PUBLICATIONS 

*     Articles

1995, 1996, 1997, 1998, 1999, 2000 

2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009

 

*     Ouvrages

 

*     Conférences invitées

 

*   Communications

1995, 1996, 1997, 1998, 1999, 2000

2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009

 

 

 

ARTICLES

2009

1.                Bun SS, Laget M, Chea A, Bun H, Ollivier E, Elias R. Cytotoxic activity of alkaloids isolated from Stefania rotunda. Phytotherapy Research, 2009, 23(4): 587-590

2.                Mercier C, Dupuis C, Blesius A, Fanciullino R, Yang CG, Padovani L, Giacometti S, Frances N, Iliadis A, Duffaud F, Ciccolini J. Early severe toxicities after capecitabine intake: Possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemotherapy Pharmacology, 2009, 63(6): 1177-1180

2008

1.                Bun SS, Elias R, Baghdikian B, Ciccolini J, Ollivier E, Balansard G. Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells. Phytotherapy Research, 2008, 22(10): 1299-1302

2.                Bun SS, Laget M.Chea A, Bun H, Ollivier E, Elias R. Cytotoxic activity of alkaloids isolated from Stephania rotunda in vitro cytotoxic activity of cepharanthine. Phytotherapy Research, 2008, 23(4): 587-590

3.                Ea S, Giacometti S, J. Ciccolini, Akhmedjanova V, Aubert C. Cytotoxic effects of Haplamine and its major metabolites on human cancer cell lines. Planta Medica, 2008, 74(10): 1265-1268

4.                Nassiry M, Aubert C, Mouzdahir A, Rontari JF. Generation of isoprenoid compounds, notably prist-1-ene, via photo and autoxidative degradation of vitamin E. Organic  Geochemistry, 2008, 40(1): 38-50

5.                Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, Pourroy B, Deville JL, Duffaud F, Bagarry-Liegey D, Durand A, Iliadis A, Favre R. High-dose methotrexate in adults with osteosarcoma: A population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs, 2008, 19(3): 267-273

6.                Rontani JF, Aubert C. Hydrogen and trimethylsilyl transfers during EI mass spectral fragmentation of hydroxycarboxylic and oxocarboxylic acid trimethylsilyl derivatives. Journal of The American Society for Mass Spectrometry, 2008, 19(1): 66-75

7.                Arlotto E, Felicé MP, Favre C, Bun H, Cornet M. Intérêt du bilan biologique d'entrée dans le despistage de comorbidités chez les patients hospitalisés en psychiatrie. L'Encéphale, 2008, 34(1): 61-65

8.                Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2008, 35(6): 619-633

9.                Barbolosi D, Benabdallah A, Hubert F, Verga F. Mathematical and numerical analysis for a model of growing metastatic tumors. Mathematical Biosciences, 2008, 218(1): 1-14

10.            Meille C, Gentet JC, Barbolosi D, André N, Doz F, Iliadis A. New adaptive method for phase I trials in oncology. Clinical Pharmacology and Therapeutics, 2008, 83(6): 873-881

11.            Huong SP, Rocher E, Fourneron JD, Charles L, Monnier V, Bun H, Andrieu V. Photoreactivity of the sunscreen butylmethoxydibenzoylmethane (DBM) under various experimental conditions. Journal of Photochemistry and Photobiology A: Chemistry, 2008, 196(1): 106-112

12.            Ea S, Aubert C, Giacometti S, Ciccolini J, Siv C, Bun H. Validation of a simple HPLC method for assay of haplamine and its metabolites in plasma suitable for pharmacokinetic application in rats. Biomedical Chromatography, 2008, 22(2): 125-130

13.            Blasco H, Boisdron-Celle M, P.Bougnoux, Calais G, Tournamille JF, Ciccolini J, Autret-Leca E, Guellec CL. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. British Journal of Clinical Pharmacology, 2008, 65(6): 966-970

2007

1.       Mercier C, Evrard A, Ciccolini J. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. Journal of Clinical Oncology, 2007, 25(30): 4855

2.       Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. British Journal of Cancer, 2007, 97(7): 919-926

3.       Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends in Pharmacological Sciences, 2007, 28(12): 597-598

4.       Karouby O, Iliadis A, Durbec JP, Riandey V, Carlotti F. Stochastic modelling for determining zooplankton abundance. Ecological Modelling, 2007, 204(3-4): 372-378

5.       Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, Blesius A, Duluc M, Franceschini F, Giacometti S, Salas S, Milano G, Favre R, Seitz JF, Ciccolini J. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenetics and Genomics, 2007, 17(10): 841-844

2006

1.       ElKababri M, André N, Coze C, Lena G, Figarella-Branger D, Gentet JC. Atypical teratoid rhabdoid tumor in a child with neurofibromatosis. Pediatric Blood and Cancer, 2006, 46(2): 267-268

2.       Andre N, Boyer M, Coze C, Delorme J, Rome A, Gentet JC, Bernard JL. Can dantrolene contribute to methotrexate toxicity? Annals of Pharmacotherapy, 2006, 40(9): 1695-1696

3.       Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Durand A, Noble A, Lacarelle B, Favre R. Dose individualization of carboplatin following 120 hours schedule: Higher dose intensity, fewer toxicities. Therapeutic Drug Monitoring, 2006, 28(2): 212-218

4.       Bun SS, Bun H, Guédon D, Rosier C, Ollivier E. Effect of green tea extracts on liver functions in wistar rats. Food and Chemical Toxicology, 2006, 44(7): 1108-1113

5.       Milano E, Pourroy B, Delarue A, Rome A, Coze C, Gorincour G, Braguer D, André N. Efficacy of a combination of pemetrexed and multiple redo-surgery in a 11-year-old girl with a recurrent multifocal abdominal mesothelioma. Anticancer Drugs, 2006, 17(10): 1231-1234

6.       Fanciullino R, Evrard A, Cuq P, Giacometti S, Peillard L, Mercier C, Aubert C, Milano G, Ciccolin J. Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: An in-vitro study. Anticancer Drug, 2006, 17(4): 463-470

7.       Quilichini B, André N, Bouvier C, Chrestian MA, Rome A, Intagliata D, Coze C, Lena G, Zattara H. Hidden chromosomal abnormalities in pleuropulmonary blastomas identified by multiplex FISH. BMC Cancer, 2006, 6(4): 1-8

8.       Flandin I, Hartmann O, Michon J, Pinkerton R, Coze C, Stephan JL, Valteau-Couanet B, Bergeron C, Philip T, Carrie C. Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma. A study of the French Society of Pediatric Oncology. International Journal of Radiation Oncology Biology Physics, 2006, 64(5): 1424-1431

9.       Ea S, Bun SS, Aubert C, Akhmedjanova V, Ollivier E, Siv C, Bun H. Interspecies variability of haplamine metabolism and identification of its phase I metabolites from liver microsomes. Planta Medica, 2006, 72(14): 1273-1278

10.     Monjanel-Mouterde S, Traoré F, Gasquet M, Dodero F, Delmas F, Ikoli JF, Chamlian AM, Portugal H, Balansard G, Pisano P. Lack of toxicity of hydroethanolic extract from Mitragyna inermis (Willd.) O. Kuntze by gavage in the rat. Journal of Ethnopharmacology, 2006, 103(3): 319-326

11.     Voeurng V, Andrieu V, Bun H, Reynier JP, Dubus JC. A new small volume holding chamber for asthmatic children: Comparison with babyhaler spacer. Pediatric Allergy and Immunology, 2006, 17(8): 629-634

12.     Larguiller R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, Francoual M, Renée N, Ferrero JM, Foa C, Namer M, Lacarelle B, Milano G. Pharmacogenetics of capecitabine is related to clinical outcome in advanced breast cancer patients. Clinical Cancer Research, 2006, 12(18): 5496-5502

13.     Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D, Mosseri V, Bergeron C, Weston C, Coze C, Auvrignon A, Djafari L, Hobson R, Baunin C, Dickinson F, Brisse H, McHugh K, Biassoni L, Giammarile F, Vassal G. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. Journal of Clinical Oncology, 2006, 24(33): 5259-5264

14.     Mercier C, Ciccolini J. Profiling DPD deficiency in patients with cancer undergoing 5-FU/capecitabine therapy. Clinical Colorectal Cancer, 2006, 6(4): 288-296

15.     Ciccolini J, Mercier C, Evrard A, Boyer JC, Duffaud F, Dahan L, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B. A rapid and inexpenseve method for anticipating severe toxicity to 5-FU based chemotherapy. Therapeutic Drug Monitoring, 2006, 28(5): 678-685

16.     Hout S, Chea A, Bun SS, Elias R, Gasquet M, Timon-David P, Balansard G, Azas N. Screening of selected indigenous plants of Cambodia for antiplasmodial activity. Journal of Ethnopharmacology, 2006, 107(1): 12-18

17.     Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination-erlotinib and 5-fluoro-5'-deoxyuridine. Anticancer Drugs, 2006, 17(7): 807-813

18.     Andre N, Meille C. Taxanes in Paediatric oncology: and now? Cancer Treatment Reviews, 2006, 32(2): 65-73

19.     Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, Monjanel-Mouterde S, Baciuchka-Palmaro M, Dupuis C, Yang C, Balti M, Lacarelle B, Duffaud F, Durand A, Favre R. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinun measurement in plasma. Therapeutic Drug Monitoring, 2006, 28(4): 532-539

20.     Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Seitz JF, Lacarelle B. Toxic death-case after capecitabine + oxaliplatin (Xelox) administration: Problable implication of dihydro-pyrimidine deshydrogenase (DPD) deficiency. Cancer Chemotherapy and Pharmacology, 2006, 58(2): 272-275

21.     Andre N, Meille C. Taxanes in paediatric oncology : And now ? Cancer Treatment Reviews, 2006, 32(2): 65-73

2005

1.       BenSalah H, Coze C, Gentet JC, Lautraite C, Andre N, Bernard JL. Autogreffes de cellules souches hématopoiétiques en Oncologie Pédiatrique; étude des complications infectieuses survenant au cours de la première année après sortie d'aplasie. Archives de Pédiatrie, 2005, 12(5): 526-532

2.       Rontani JF, Aubert C. Characterization of isomeric allylic diols resulting from chlorophyll phytyl side-chain photo-and autoxidation by electron ionization gas chromatography/mass spectrometry. Rapid Communication in Mass Spectrometry, 2005, 19(5): 637-646

3.       Fanciullino R, Giacometti S, Aubert C, Fina F, Martin PM, Piccerelle P, Ciccolini J. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: In vitro and in vivo study. Pharmaceutical Research, 2005, 22(12): 2051-2057

4.       Geoerger B, Vassal G, Doz F, O'Quigley J, Wartelle M, Watson AJ, Raquin MA, Frappaz D, Chastagner P, Gentet JC, Rubie H, Couanet D, Geoffray A, Djafari L, Margison GP, Pein F. Dose finding and 06-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. British Journal of Cancer, 2005, 93(5): 529-537

5.       Bun SS, Giacometti S, Fanciullino R, Ciccolini J, Bun H, Aubert C. Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. Anti-Cancer Drugs, 2005, 16(6): 675-682

6.       Rontani JF, Aubert C. Electron ionization mass spectral fragmentation of cholestane-3b,4a,5a-triol and cholestane-3b,5a,6a/b-triol bis and tris-trimethylsilyl derivatives. Rapid Communication in Mass Spectrometry, 2005, 19(14): 1921-1927

7.       Hanna S, Gharib B, Lepidi H, Montet JC, Dumon H, Reggi M. Experimental schistosomiasis, protective aspects of granulomatous reaction in the mouse liver. Parasitology Research, 2005, 96(1): 6-11

8.       Montet JC, Caroli-Bosc FX, Ferrari P, Piche T, Baize N, Anty R, Montet AM, Rampal P, Tran A. Gallbladder motility and gut hormone plasma levels in subjects with and without gallstones. Gastroenterologie Clinique et Biologique, 2005, 29(5): 569-572

9.       Ciccolini J, Mercier C, Fanciullino R, Richard K, Etienne MC, Seitz JF, Favre R, Milano G, Lacarelle B. Impact du déficit en DPD sur la iatrogénie des fluoropyrimidines. Bulletin du Cancer, 2005, 92(6): 550

10.     Fanciullino R, Bun SS, Vanelle P, Michel BF. La protection des anti-inflammatoires non stéroïdiens contre la maladie d'Alzheimer. L'Année Gérontologique, 2005, 19(1): 303-318

11.     Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defachelle AS, Hartmann O. Metastatic osteosarcoma at diagnosis:Pprognostic factors and long-term outcome,  the French pediatric experience. Cancer, 2005, 104(5): 1100-1109

12.     Iliadis A. Optimizing drug regimens in cancer chemotherapy. Basic and Clinical Pharmacology and Toxicology, 2005, 96(3): 269-270

13.     Bendiane MK, Perreti-Watel P, Galiner A, Favre R, Obadia Y. Prescription de morphine en cas de douleur intense en phase terminale de cancer: résultats d'une enquête nationale. Bulletin du Cancer, 2005, 92(7-8): 733-740

14.     Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, Bui NB, Burgat R, Chayvialle JA, Rougier P, Bouché O, Bonichon F, Lassau N, Vanel D, Nordlinger B, Stoeckle E, Meeus P, Coindre JM, Scoazec JY, Emile JF, Ranchère D, LeCesne A. Recommendations for the management of GIST patients. Bulletin du Cancer, 2005, 92(10): 907-910

15.     Bozec A, Formento P, Ciccolini J, Fanciullino R, Padovani L, Murraciole X, Fischel JL, Milano G. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Molecular Cancer Therapeutics, 2005, 4(12): 1692-1971

16.     Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, Rubie H, Coze C, Plantaz D, Bernard F, Chastagner P, Bouzy J, Hartmann H. Results of induction chemotherapy in children older than I year with a stage 4 neuroblastoma (NB) treated with the NB 97 SFOP protocol. Journal of Clinical Oncology, 2005, 23(3): 532-540

17.     Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, Sariban E, Pagnier A, Badin A, Pichon F, Neuenschwander S, Vinchon M, Bours D, Mosseri V, Gales CL, Ruchoux M, Carrie C, Doz F. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. Journal of Clinical Oncology, 2005, 23(21): 4726-4734

18.     Claude L, Rousmans S, Carrie C, Breteau N, Dijoud F, Gentet JC, Giammarile F, Jouve JL, Kind M, Marec-Berard P, Mascard E, Bataillard A, Philip T. Standards and options for the use of radiation therapy  in the management of patients with osteosarcoma. Bulletin du Cancer, 2005, 92(10): 891-906

19.     Teral Y, Roubaud G, Aubert C, Faure R, Campredon M. Synthesis and NMR spectroscopic characterization of some Fluoro-2H-1-Benzopyran derivatives. Australian Journal of Chemistry, 2005, 96(1): 6-11

20.     Fischel JL, Ferrero JM, Formento P, Ciccolini J, Renee N, Formento JL, Milano G. Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells. Anti-Cancer Drugs, 2005, 16(3): 309-316

21.     Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi A, Chastagner P, Couanet D, Habrand JL, Raquin MA, LeDeley MC, Kalifa C. Treatment of medulloblastoma with postoperative chemotherapy alone: An SFOP prospective trial in young children. Lancet Oncology, 2005, 6(8): 573-580

22.     Rontani JF, Rabourdin A, Pinot F, Kandel S, Aubert C. Visible light-induced oxidation of unsaturated components of cutins: A significant process during the senescence of higher plants. Phytochemistry, 2005, 66(3): 313-321

2004

1.       Guitaoui M, Parquet M, Aubert C, Montet AM, Montet JC. Conjugaison with taurine prevents side-chain desaturation of ursodeoxycholic and b-muricholic acids in rats. Fundamental and Clinical Pharmacology, 2004, 18(4): 457-464

2.       Rontani JF, Aubert C. Electron ionization mass spectral fragmentation of derivatized 4,5- and 5,6-epoxysterols. Rapid Communication in Mass Spectrometry, 2004, 18(9): 955-959

3.       Evrard A, Ciccolini J, Cuq P, Cano JP. Enzyme-prodrug systems: thymidine phosphorylase/5'-deoxy-5-fluorouridine. Methods in Molecular Medecine, 2004, 90: 236-278

4.       Duffaud F, Borner M, Chollet P, Vermorken JB, Bonneterre M, Rolland F, Dittrich C, Baron B, Lacombe D. For the EORTC-New drug development Group/New drug development program. Phase II study of NX211 (liposomal lurtotecan) given as an IV infusion over 30 minutes on days 1 and 8 every 3 weeks in patients with metastatic or locoregional recurrent squamous cell carcinoma of the head and neck with target lesions within previously irradiated fields or outside previosly irradiated fields. European Journal of Cancer, 2004, 40(18): 2748-2752

5.       Andre N, Coze C, Gentet JC, Perez R, Bernard JL. Geotrichum candidum septicemia in a child with hepatoblastoma. Pediatric Infectious Disease Journal, 2004, 23(1): 86

6.       Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, DePontual L, Schleiermacher G, Coze C, Philip N, Frebourg T, Munnich A, Lyonnet S, Delattre O, Amiel J. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. American Journal of Human Genetics, 2004, 74(4): 761-764

7.       Dokoumetzidis A, Karalis V, Iliadis A, Macheras P. The heterogeneous course of drug transit through the body. Trends in Pharmacological Sciences, 2004, 25(3): 140-146

8.       Laprie A, Michon J, Hartmann O, Munzer C, Leclair MD, Coze C, Valteau-Couanet D, Plantaz D, Carrie C, Habrand JL, Bergeron C, Chastagner P, Defachelle AS, Delattre O, Combaret V, Bernard J, Perel Y, Gandemer V, Rubie H. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system stage II and III neuroblastoma with MYCN amplification. Cancer, 2004, 101(5): 1081-1089

9.       Fischel JL, Formento P, Ciccolini J, Etienne-Grimaldi MC, Milano G. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotox 5'-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs, 2004, 15(10): 969-974

10.     Perel Y, Valteau-Couanet D, Michon J, Lavrand F, Coze C, Bergeron C, Notz A, Plantaz D, Chastagner P, Bernard F, Thomas C, Rubie H. Le pronostic du neuroblastome de l'enfant. Méthodes d'étude et utilisation en pratique clinique. Archive Pédiatrique, 2004, 11: 834-842

11.     Cannone P, Dudoit E, Dany L, Duffaud F, Favre R. L'étude des représentations sociales de la chimiothérapie: une voie d'analyse de relations entre patients et médecins oncologues. Bulletin du Cancer, 2004, 92(3): 279-284

12.     Michalowski MB, Rubie H, Michon J, Montamat S, Bergeron C, Coze C, Perel Y, Valteau-Couanet D, Guitard JM, Guys JM, Piolat C, Munzer C, Plantaz D. Neuroblastomes localisés du nouvé-né: 52 cas traités de 1990 à 1999. Archives de Pediatrie, 2004, 11(7): 782-788

13.     Ciccolini J, Mercier C, Blachon MF, Fabre R, Durand A, Lacarelle B. A simple and rapid high-performance liquid chromatographic  (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. Journal of Clinical Pharmacy and Therapeutics, 2004, 29(4): 307-315

14.     Ciccolini J, Evrard A, Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: A Jekyl and Hyde story. Current Medicinal Chemistry Anti-Cancer Agents, 2004, 4(2): 71-81

15.     Boulamery-Velly A, Mercier C, Duffaud F, Duffaud R, Favre R, Digue L, LaScola B. Totally implatable intravascular devices-related complications: Effectiveness of insertion by trained team. Journal of Hospital Infection, 2004, 56(3): 248-249

16.     Rontani JF, Aubert C. Trimethlysilyl transfer during electron ionization mass spectral fragmentation of some w-hydroxycarboxylic and w-dicarboxylic acid trimethylsilyl derivatives and the effect of chain length. Rapid Communication in Mass Spectrometry, 2004, 18(17): 1889-1895

17.     Salas S, Tuzzolino V, Duffaud F, Mercier C, Dudoit E, Favre R. Utilisation de la Ketamine en soins palliatifs: Revue de la littérature. Medecine Palliative, 2004, 3(6): 277-284

2003

1.       Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Leyer L, Lavaut MJ, Allasia C, Charpin C. CD105 expression in 929 breast carcinomas: Correlation of immunocytochemical assays to patients' long term follow-up. American Journal of Clinical Pathology, 2003, 119(3): 374-380

2.       Vertzoni M, Symillides M, Iliadis A, Nicolaides E, Reppas C. Comparison of simulated cumulative drug versus time data sets with indices. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56(3): 421-428

3.       Perreti-Watel P, Bendiane MK, Pegliasco H, Lapiana JM, Favre R, Galinier A, Moatti JP. Doctor's opinions on euthanasia, end of life care, and doctor-patient communication; telephone survey in France. British Medical Journal, 2003, 327(7415): 595-596

4.       Bun SS, Ciccolini J, Catalin J, Aubert C, Bun H. Drug interactions of paclitaxel metabolism in human liver microsomes. Journal of Chemotherapy, 2003, 15(3): 266-274

5.       Rontani JF, Aubert C. Electron ionization mass spectral fragmentation of C19 isoprenoid aldehydes and carboxylic acid methyl and trimethylsilyl esters. Rapid Communication in Mass Spectrometry, 2003, 17(9): 949-956

6.       VanDeBrande J, Schoffski P, Schellens J, Roth A, Duffaud F, Weigang K, Reinke F, Wanders J, DeBoer R, Fumoleau P. EORTC early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. British Journal of Cancer, 2003, 88(5): 648-653

7.       Bezulier K, Fina F, Roussel M, Bun SS, Ciccolini J, Martin PM, Aubert C, Barra Y. Fas/FasL expression in tumor biopsies: A prognosic response factor to fluoropyrimidines? Journal of Clinical Pharmacy and Therapeutics, 2003, 28(5): 403-408

8.       Perreti-Watel P, Bendiane MK, Galinier A, Favre R, Lapiana JM, Pegliasco H, Moatti JP. French physicians attitudes toward legalisation of euthanasia and the ambiguous retionship between euthanasia and palliative care. Journal of Palliative Care, 2003, 19(4): 271-277

9.       Duffaud F, Blay JY. Gastrointestinal stromal tumors: Biology and treatment. Oncology, 2003, 65(3): 187-197

10.     Rubie H, Doz F, Vassal G, Chastagner P, Gentet JC, Urien S, Bastian G, Drouard-Troalen L, Barberi-Heyob M, Catalin J, Chatelut E. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy. European Journal of Cancer, 2003, 39(10): 1433-1438

11.     Bun SS, Voeurng V, Bun H. Interspecies variability and drug interactions of loxapine metabolism in liver microsomes. European Journal of Drug Metabolism and Pharmacokinetics, 2003, 28(4): 295-300

12.     Rubie H, Coze C, Plantaz D, Munzer C, Defachelles AS, Bergeron C, Thomas C, Chastagner P, Valteau-Couanet D, Michon J, Mosseri V, Hartmann O. Localized and unresectable neuroblastoma in infants: Excellent outcome with low-dose primary chemotherapy. British Journal of Cancer, 2003, 89(9): 1605-1609

13.     Magné N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renée N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G. Molecular mecanisms underlying the interaction between ZD1839 ("Uressa") and cisplatin/5-fluorouracil. British Journal of Cancer, 2003, 89(3): 585-592

14.     Gaspar N, Hartmann O, Munzer C, Bergeron C, Millot F, Cousin-Lafay L, Babin-Boilletot A, Blouin P, Pajot C, Coze C. Neuroblastoma in adolescents. Cancer, 2003, 98(2): 349-355

15.     Barbolosi D, Freyer G, Ciccolini J, Iliadis A. Optimisation de la posologie et des modalités d'administration des agents cytotoxiques à l'aide d'un modèle mathématique. Bulletin du Cancer, 2003, 90(2): 167-175

16.     Goncalves A, Viret F, Ciccolini J, Genre D, Gravis G, Giovanini M, Camerlo J, Catalin J, Maraninchi D, Viens P. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clinical Cancer Research, 2003, 9(1): 102-108

17.     Rontani J, Rabourdin A, Marchand D, Aubert C. Photochemical oxidation and autoxidation of chlorophyll phytyl side chain in senescent phytoplanktonic cells: Potential sources of several acyclic isoprenoid compounds in the marine environment. Lipids, 2003, 38(3): 241-254

18.     Monjanel-Mouterde S, Ciccolini J, Merite N, Duffaud F, Favre R, Durand A. Population pharmacokinetics of cisplatin: Application to routine dose individualization. Journal of Clinical Pharmacy and Therapeutics, 2003, 28(2): 109-116

19.     Perreti-Watel P, Bendiane MK, Obadia Y, Favre R, Lapiana JM, Moatti JP. The prescription of opioid analgesics to terminal cancer patients: Impact of physicians general attitudes and contextual factors. Palliative and Supportive Care, 2003, 1(4): 345-352

20.     Duffaud F, Digue L, Mercier C, Dales JP, Baciuchka-Palmaro M, Volot F, Thomas P, Favre R. Reccurences following primary osteosarcoma in adolescents and adults previosly reated with chemotherapy. European Journal of Cancer, 2003, 39(14): 2050-2057

21.     Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renée N, Marchetti S, Etienne MC, Milano G. ZD 1839 ("Iressa") modifies the activity of key enzymes linked to fluoropyrimidine activity. Rational basis for a new combination therapy with capecitabine. Clinical Cancer Research, 2003, 9(13): 4735-4742

22.     Dales JP, Garcia S, Bonnier P, Duffaud F, Meunier-Carpentier S, Andrac-Meyer L, Lavaut MJ, Allasia C, Charpin C. Tie2/Tek expression in breast carcinoma: Correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients. International Journal of Oncology, 2003, 22(2): 391-397

23.     Dales J, Garcia S, Bonnier P, Duffaud F, Carpentier S, Djemli A, Ramuz O, Andrac-Meyer L, Lavaut MJ, Allasia C, Charpin C. Valeur pronostique de l'expression des récepteurs du VEGF, VEGFR-1 (FLT-1) et VEGFR-2 (KDR/FLK-1) dans le cancer du sein. Annales de Pathologie, 2003, 23(4): 297-305

2002

1.       Baciuchka-Palmaro M, Orsière T, Duffaud F, Sari-Minodier I, Pompili J, Bellon L, DeMeo M, Digue L, Favre R, Botta A. Acentromeric micronuclei are increased in peripheral blood lymphocytes of untreated cancer patients. Mutation Research, 2002, 520(1-2): 189-198

2.       Monjanel-Mouterde S, Lejeune C, Ciccolini J, Mérité N, Hadjaj D, Bonnier P, Piana P, Durand A. Bayesian application of a population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. Journal of Clinical Pharmacy and Therapeutics, 2002, 27(3): 189-195

3.       Montet AM, Oliva L, Beaugé F, Montet JC. Bile salts modulate chronic ethanol-induced hepatotoxicity. Alcohol and Alcoholism, 2002, 37(1): 25-29

4.       Doz F, Neuenschwander S, Bouffet E, Gentet JC, Schneider P, Kalifa C, Mechinaud F, Chastagner P, DeLumley L, Sariban E, Plantaz D, Mosseri V, Bours D, Alapetite C, Zucker JM. Carboplatin before and during radiation therapy for the malignant brain stem tumours a study by the Societé Française d'Oncologie Pédiatrique. European Journal of Cancer, 2002, 38(6): 815-819

5.       Fernandez C, Bouvier C, Sevenet N, Liprandi A, Coze C, Lena G, Figarella-Branger D. Congenital disseminated malignant rhabdoid tumor and cerebellar tumor mimicking medulloblastoma in monozygotic twins: Pathologic and molecular diagnosis. American Journal of Surgical Pathology, 2002, 26(2): 266-270

6.       Fischel JL, Formento JL, Ciccolini J, Rostagno P, Etienne MC, Catalin J. Impact of the oxaliplatin-5 fluorouracil - folinic acid combination on respective intracellular determinations of drug activity. British Journal of Cancer, 2002, 86(7): 1162-1168

7.       Digue L, Orsiere T, Baciuchka-Palmaro M, Duffaud F, Pompili J, Favre R, Botta A. Intérêt de l'étude de la génotoxicité in vitro d'une molécule de chimiothérapie sur cellules humaines: exemple du paclitaxel. Bulletin du Cancer, 2002, 89(10): 887-892

8.       Carré M, Carles G, André N, Douillard S, Ciccolini J, Briand C, Braguer D. Involvement of microtubules and mitochondria in the antagonism of arsenic trioxyde on paclitaxel-induced apoptosis. Biochemical Pharmacology, 2002, 63(10): 1831-1842

9.       Frappaz C, Perol D, Michon J, Berger C, Coze C, Bernard JL, Zucker JM, Philip T. The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over one year at diagnosis. British Journal of Cancer, 2002, 87(11): 1197-1203

10.     Dokoumetzidis A, Iliadis A, Macheras P. Nonlinear dynamics in clinical pharmacology: The paradigm of cortisol secretion and suppression. British Journal of Clinical Pharmacology, 2002, 54(1): 21-29

11.     Caponigro F, Dittrich C, Sorensen JB, Schellens JHM, Duffaud F, PazAres L, Lacombe D, Balincourt C, Fumoleau P. Phase II study of XR 5000, an inhibitor fo topoisomerases I and II, in advanced colorectal cancer. European Journal of Cancer, 2002, 38(1): 70-74

12.     Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, Cuq P, Romain S, Martin PM, Aubert C. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Molecular Cancer Therapeutics, 2002, 1(11): 923-927

13.     Ciccolini J, Monjanel-Mouterde S, Bun SS, Blanc C, Duffaud F, Favre R, Durand A. Population pharmacokinetics of etoposide: Application to therapeutic drug monitoring. Therapeutic Drug Monitoring, 2002, 24(6): 709-714

2001

1.       Vallée S, Monjanel-Mouterde S, Baggary D, Duffaud F, Moretto C, Grabowski S, Ciccolini J, Favre R, Durand A. Adaptation individuelle de posologie du methotrexate (MTX) chez un insuffisant rénal sévère; danger de la méthode bayesienne. Journal de Pharmacie Clinique, 2001, 20(4): 225-228

2.       Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, Cano JP, Iliadis A. Combination of Thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics, 2001, 1(2): 133-139

3.       DeHaro L, Valli M, Bourdon JH, Iliadis A, Hayek-Lanthois M, Arditti J. Diazepam poisoning with one-month monotoring of diazepam and nordiazepam blood levels. Veterinary and Human Toxicology, 2001, 43(3): 174-175

4.       Correia L, Podevin P, Borderie D, Verthier N, Montet JC, Feldman G, Poupon R, Weill B, Calmus Y. Effects of bile acids on the humoral immune response: A mechanistic approach. Life Sciences, 2001, 69(20): 2337-2348

5.       Podevin P, Correia L, Montet JC, Conti F, Chéreau C, Calmus Y, Poupon R. Effects of bile salts and aliphatic ionic surfactants on human lymphocyte proliferation. European Journal of Clinical Investigation, 2001, 31(4): 367-373

6.       Rontani JF, Rabourdin A, Aubert C. Electron ionization mass spectral fragmentation of some isoprenoid glycidic ethers. Rapid Communication in mass Spectrometry, 2001, 15(22): 2091-2095

7.       Cuq P, Rouquet C, Evrard A, Ciccolini J, Vian L, Cano JP. Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. British Journal of Cancer, 2001, 84(12): 1677-1680

8.       Karalis V, Claret L, Iliadis A, Macheras P. Fractal volume of drug distribution: It scales proportionally to body mass. Pharmaceutical Research, 2001, 18(7): 1056-1060

9.       Petricoul O, Claret L, Barbolosi D, Iliadis A, Puozzo C. Information tools for exploratory data analysis in population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28(6): 577-599

10.     Rubie H, Plantaz D, Coze C, Michon J, Frappaz D, Baranzelli MC, Chastagner P, Peyroulet MC, Hartmann O. Localised and unresectable neuroblastoma in infants: excellent-outcome with primary chemotherapy. Neuroblastoma study Group, Societe Française d'Oncologie Pediatrique. Medical and Pediatric Oncology, 2001, 36(1): 247-250

11.     Ba BB, Bernard A, Iliadis A, Quentin C, Ducint D, Etienne R, Fourtillan M, Maachi-Guillot I, Saux MC. New approach for accurate simulation of human pharmacokinetics in a in vitro pharmacodynamic model. Application to ciprofloxacin. The Journal of Antimicrobial Chemotherapy, 2001, 47(2): 223-227

12.     Dokoumetzidis A, Iliadis A, Macheras P. Nonlinear dynamics and chaos theory: Concepts and applications relevant to pharmacodynamics. Pharmaceutical Research, 2001, 18(4): 415-426

13.     Barbolosi D, Iliadis A. Optimizing drug regimens in cancer chemotherapy: A simulation study using a PK-PD model. Computers in Biology and Medicine, 2001, 31(3): 157-172

14.     Philip T, Blay JY, Brunat-Mentigny M, Carrie C, Chauvot P, Farsi F, Fervers B, Gentet JC, Giammarile F, Kohler R, Mathoulin S, Patricot LM, Thiesse P. Osteosarcoma. British Journal of Cancer, 2001, 84(S2): 78-80

15.     Bernard JL, Lautraite C, Reyes P, Portas M. Pains in children a pediatrician's point of view. Therapie, 2001, 56(6): 705-709

16.     Doz F, Gentet JC, Pein F, Frappaz D, Chastagner G, Moretti S, Vassal G, Arditti I, VanTellingen O, Iliadis A, Catalin J. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumor: A SFOP Study. British Journal of Cancer, 2001, 84(5): 604-610

17.     Goncalves A, Camerlo J, Bun H, Gravis G, Genre D, Bertucci F, Resbeut M, Pech-Gourg F, Durand A, Maraninchi D, Viens P. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-a in squamous cell carcinoma: Clinical  résults and pharmacokinetics. Anticancer Research, 2001, 21(2B): 1431-1437

18.     Grill J, LeDeley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC, Edan C, Chastagnier P, Kalifa C. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. Journal of Clinical Oncology, 2001, 19(5): 1288-1296

19.     Moukheiber AK, Nicollas R, Roman S, Coze C, Triglia JM. Primary pediatric neuroblastic tumors of the neck. International Journal of Pediatric Otorhinolaryngology, 2001, 60(2): 155-161

20.     Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, Carrie C, Mechinaud F, Schmitt C, Babin-Boilletot A, Michon J. Pronostic factors in localisezed Ewing's tumours and peripheral neuroectodermal tumors: The third study of the French Society of Paediatric Oncology. British Journal of Cancer, 2001, 85(11): 1646-1654

21.     Ciccolini J, Catalin J, Blachon MF, Durand A. Rapid high-performance liquid chromatography determination of docetaxel (Taxotere®) in plasma using liquid-liquid extraction. Journal of Chromatography. B, Biomedical Sciences and Applications, 2001, 759(2): 299-306

22.     Coze C, Leimig T, Jimeno MT, Mannoni P. Retrovirus-mediated gene transfer of the cytokine genes interleukin-1beta and tumor necrosis factor-apha into human neuroblastoma cells: Consequences for cell line behavior and immunomodulatory properties. European Cytokine Network, 2001, 12(1): 78-86

23.     Caroli-Bosc FX, LeGall P, Pugliese P, Delabre B, Caroli-Bosc C, Demarquay JF, Delmont JP, Rampal P, Montet JC. Role of fibrates and HMG CoA reductase inhibitors in gallstone formation. Epidemiologic study in an unselected population. Digestive Diseases and Sciences, 2001, 46(3): 540-544

24.     Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphael M, Terrier-Lacombe MJ. The Society Française d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 inselected children with B-cell lymphomas and L3 leukemia. Blood, 2001, 97(11): 3370-3379

25.     Claret L, Iliadis A, Macheras P. A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28(5): 445-463

26.     BenMouaz A, Lindheimer M, Montet JC, Zajac J, Lagerge S. A study of the adsorption of bile salts onto model lecithin membranes. Colloids and Surfaces B, Biointerfaces, 2001, 20(2): 119-127

27.     Dalle JH, Mechinaud F, Michon J, Gentet JC, DeLumley L, Rubie H, Schmitt C, Patte C. Testicular disease in childhood b-cell non -Hodgkin's lymphoma: The French Society of Pediatric Oncology experience. Journal of Clinical Oncology, 2001, 19(9): 2397-2403

28.     Michel C, Brugna M, Aubert C, Bernadac A, Bruschi M. Enzymatic reduction of chromate: Comparative studies using sulfate-reducing bacteria. Key role of polyheme cytochromes c and hydrogenases. Applied Microbiology and Biotechnology, 2001, 55(1): 95-100

29.     Salmon L, J.C.Montet, Oddoze C, Montet AM, Portugal H, Michel B. Ursodeoxycholic acid and prevention of tacrine-induced hepatotoxicity. A pilot study. Thérapie, 2001, 56(1): 29-34

30.     Wu G, Yan SM. Cyclosporine therapeutic and toxic effects may be related to different cyclosporine concentration zones in plasma. Medical Hypotheses, 2001, 56(5): 691-692

2000

1.       Philip T, Blay JY, Brunat-Mentigny M, Carrie C, Chauvot P, Farsi F, Fervers B, Gentet JC, Giammarile F, Kolher R, Mathoulin S, Patricot LM, Thiesse P. Standards, options et recommandations (SOR) pour le diagnostic, le traitement et la surveillance des ostéosarcomes. Groupe de Travail SOR. Bulletin du Cancer, 1999, 86(2): 159-176

2.       Minard V, Hartmann O, Peyroulet MC, Michon J, Coze C, Defachelle AS, Lejars O, Perel Y, Bergeron C, Boutard P, Leverger G, J.L.Stephan, Thyss A, Chastagner P, Couillault G, Devalck C, Lutz P, Mechinaud F, Millot F, Plantaz D, Rialland X, Rubie H. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: Results of the French society of pediatric oncology. British Journal of Cancer, 2000, 83(8): 973-979

3.       Wu G. Another integrated form of the Michaelis-Menten equation, its analogy to electrical circuit model and implications for active transporters. Medical Hypotheses, 2000, 54(5): 748-749

4.       Grossi V, Raphel D, Aubert C, Rontani JF. The effect of growth temperature on the long chain alkenes composition in the marine coccolithorphorid Emiliana huxleyi. Phytochemistry, 2000, 54(4): 393-399

5.       Ciccolini J, Peillard L, Evrard A, Cuq P, Aubert C, Pelegrin A, Formento P, Milano G, Catalin J. Enhanced antitumor activity of 5- FU in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clinical Cancer Research, 2000, 6(4): 1529-1535

6.       Fellay-Reynier I, Orsiere T, Sari-Minodier I, Auquier P, Zattara-Cannoni H, Capodano AM, Coze C, DeMeo M, Bernard JL, Botta A. Evaluation of micronucleated lymphocytes, constitutional karyotypes and anti-p53 antibodies in 21 children with various malignancies. Mutation Research, 2000, 467(1): 31-39

7.       Disdier B, Marchetti MN, Bun H, Placidi M, Durand A. Kinetics of tissue distribution and excretion of 9-cis-retinoic acid in rat. Skin Pharmacology and Applied Skin Physiology, 2000, 13(1): 9-16

8.       Frappaz D, Michon J, Coze C, Berger C, Plouvier E, Lasset C, Bernard JL, Stephan JL, Bouffet E, Buclon M, Combaret V, Fourquet A, Philip T, Zucker JM. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. Journal of Clinical Oncology, 2000, 18(3): 468-476

9.       Landman-Parker J, Pacquement H, Leblanc T, Habrand JL, Terrier-Lacombe MJ, Bertrand Y, Perel Y, Robert A, Coze C, Thuret I, Donadieu J, Schaison G, Leverger G, Lemerle J, Oberlin O. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy -- Results of the French Society of Pediatric Oncology Study MDH90. Journal of Clinical Oncology, 2000, 18(7): 1500-1507

10.     Ciccolini J, Peillard L, Aubert C, Formento P, Milano G, Catalin J. Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: Application in modulation of metabolism and cytotoxicity study. Fundamental and Clinical Pharmacology, 2000, 14(2): 147-154

11.     Valsami G, liadis A, Macheras P. Non-linear regression analysis with errors in both variables: Estimation of co-operative binding parameters. Biopharmaceutics and Drug Disposition, 2000, 21(1): 7-14

12.     Plantaz D, Michon J, Valteau-Couanet D, Coze C, Chastagner P, Bergeron C, Nelken B, Martelli H, Peyroulet MC, Carpentier A, Amari-Alla C, Pagnier A, Rubie H. Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists. Archives de Pediatrie, 2000, 7(6): 621-628

13.     Iliadis A, Barbolosi D. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Computers and Biomedical Research, 2000, 33(3): 211-226

14.     Mabro M, Cohn R, Zanesco L, Madon E, Hahlen K, Margueritte G, Breatnach F, Gentet JC, Plouvier E. Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: Double-blind study of 2 doses. Bulletin du Cancer, 2000, 87(3): 259-264

15.     Aubert C, Rontani JF. Perfluoroalkyl ketones: Novel derivatization products for the sensitive determination of fatty acids by gas chromatography/mass spectrometry in electron impact and negative chemical ionization modes. Rapid Communication in Mass Spectrometry, 2000, 14(11): 960-966

16.     Monjanel-Mouterde S, Frenay C, Catalin J, Durand A, Boutin C, Astoul P. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions. Oncology Reports, 2000, 7(1): 171-175

17.     Wu G, Yan S. Prediction of two- and three-amido-acid sequences of citobacter Freundii b-lactamase from its amido acid composition. Journal of Molecular Microbiology and Biotechnology, 2000, 2: 277-281

18.     Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, Lena G, Choux M, Pellissier JF. Prognostic factors in intracranial ependymomas in children. Journal of Neurosurgery, 2000, 93(4): 605-613

19.     Bouffet E, Raquin M, Doz F, Gentet JC, Rodary C, Demeocq F, Chastagner P, Lutz L, Hartmann O, Kalifa C. Radiotherapy followed by high dose busulfan and thiotepa: A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer, 2000, 88(3): 685-692

20.     Horschowski N, Camoin-Jau L, Bardin N, Brunet C, Arnoux I, Guitard AM, Fossat C, Hassoun E, Coze C, Gentet JC, Bernard JL, Thuret I, Michel G, Dignat-George F. Subcutaneous lymphoblastic lymphomas. Expression of cellular adhesion molecules: 2 cases. Hematology and Cell Therapy, 2000, 42(2-3): 160-164

21.     Caroli-Bosc FX, Iliadis A, Salmon L, Macheras P, Montet AM, Bourgeon A, Garraffo R, Delmont JP, Montet JC. Ursodeoxycholic acid modulates Cyclosporin A oral absorption in liver transplant recipients. Fundamental and Clinical Pharmacology, 2000, 14(6): 601-609

22.     Vincent-Salomon A, Mathiot C, Macintyre E, Girre V, Fourquet A, Mercier C, Freneaux P, Dumont J, Decaudin D. T-Cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma. Leukemia and Llymphoma, 2000, 37(3-4): 387-391

1999

1.       Dokoumetzidis A, Iliadis A, Macheras P. An alternative method for the estimation of the terminal slope when a few data points are available. Journal of Pharmaceutical Sciences, 1999, 88(5): 557-560

2.       Bouvier C, Zattara-Canoni H, Daniel L, Gentet JC, Lena G, Figarella-Branger D. Cerebellar papillary meningioma in a 3-year-old boy: The usefulness of electron microscopy for diagnosis. The American Journal of Surgical Pathology, 1999, 23(7): 844-848

3.       Disdier B, Llorca PM, Lancon C, Farisse J, Bun H, Cornet M. Concentrations plasmatiques de la clozapine et de ses métabolites chez les patients schizophrénes résistants. Journal de Pharmacie Clinique, 1999, 18(3): 244-250

4.       LeGales C, Costet N, Gentet JC, Kalifa C, Frappaz D, Edan C, Sariban E, Plantaz D, Doz F. Cross-cultural adaptation of a health status classification system in children with cancer. First results of the French adaptation of the Health Utilities Index Marks 2 and 3. International Journal of Cancer, 1999, 83(S12): 112-118

5.       Nguyen TD, Oliva L, Villard PH, Puyoou F, Sauze C, Montet AM, Lacarelle B, Durand A, Montet JC. CYP2E1 and CYP3A1/2 gene expression is not associated with the ursodeoxycholate effect on ethanol-induced lipoperoxidation. Life Sciences, 1999, 65(11): 1103-1113

6.       BenMouaz A, Lindheimer M, Montet AM, Lagerge S, Montet JC. Dissolution of cholesterol - calcium bilirubinate compressed discs by microemulsions. New Journal of Chemistry, 1999, 23(3): 291-296

7.       Caroli-Bosc FX, Montet JC, Salmon L, Demarquay JF, Dumas R, Montet AM, Delmont JP. Effect of endoscopic sphincterotomy on bile lithogenicity in patients with gallbladder in situ. Endoscopy, 1999, 31(6): 437-441

8.       Caroli-Bosc FX, Pugliese P, Peten E, Demarquay JF, Montet JC, Hastier P, Staccini P, Delmont JP. Gallbladder volume in adults and its relationship to age, sex, body mass index, body surface area and gallstones: An epidemiologic study in a non selected population in France. Digestion, 1999, 60(4): 344-348

9.       Philip T, Iliescu C, Demaille MC, Pacquement H, Gentet JC, Krakowski I, Soler-Michel P, Thiesse P, Chauvin F, Blay JY, Brunat-Mentigny M. High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Federation Nationale des Centres de Lutte contre le Cancer and Societe Francaise d'Oncologie Pediatrique. Annals of Oncology, 1999, 10(9): 1065-1071

10.     Pillon P, Bernard-Couteret E, Bernard JL. Incidence of childhood differentiated thyroid cancer in Provence Alpes-Cote d'Azur and Corsica regions during 1984-1994. Medical and Pediatric Oncology, 1999, 33(4): 428-429

11.     Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5'-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymine phosphorylase. British Journal of Cancer, 1999, 80(11): 1726-1733

12.     Lautraite C, Andre N, Portas M, Bernard JL. Intérêt de l'administration du fentanyl transdermique dans les soins palliatifs chez l'enfant. Archives de Pediatrie, 1999, 6(7): 801-802

13.     Bun H, Disdier B, Aubert C, Catalin J. Interspecies variability and drug interactions of clozapine metabolism by microsomes. Fundamental and Clinical Pharmacology, 1999, 13(5): 577-581

14.     Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B, Trillet-Lenoir V, Canal P, Lochon I, Ardiet CJ. A limited sampling strategy for estimating etoposide pharmacokinetics in cancer patients. Cancer Chemotherapy and Pharmacology, 1999, 43(4): 316-322

15.     Boespflug MD, Bourliere-Najean B, Panuel M, Petit P, Doucet V, Gentet JC, Dubus JC, Devred P. Pulmonary anthracosis in children. European Radiology, 1999, 9(3): 485-486

1998

1.       Martin N, Catalin J, Blachon MF, Durand A. Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Sciences and Applications, 1998, 709(2): 281-288

2.       Monjanel-Mouterde S, Lafforgue P, Blanc A, Catalin J, Aquaviva C. Bayesian calculation of methotrexate clearance after low-dose of intra-muscular administration in  patients with Rheumatoïd. Journal of Rheumatology, 1998, 25(7): 1276-1280

3.       Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, Bernard JL. Clinical features of Behcet's disease in children: An international collaborative study of 86 cases. Journal of Pediatrics, 1998, 132(4): 721-725

4.       Portas M, Marty JY, Buttin C, Gentet JC, Coze C, Fallouh K, Bernard JL, Camboulives J. Douleur réfractaire chez l'enfant atteint de cancer: intérêt de l'analgésie péridurale. Archives de Pediatrie, 1998, 5(8): 851-860

5.       Villard PH, Seree E, Re JL, DeMeo M, Barra Y, Attolini L, Dumenil G, Catalin J, Durand A, Lacarelle B. Effects of tabacco smoke on the gene expression of the Cyp1a, Cyp2b and Cyp3a sulfamilies in mouse liver and lung: Relation to single starnd breaks of DNA. Toxicology and Applied Pharmacology, 1998, 148(2): 195-204

6.       Pein F, Michon J, Valteaucouanet D, Quintana E, Frappaz D, Vannier JP, Philip T, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Zucker JM, Tournade T, Hartmann H. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms-Tumor - A French Society of Pediatric Oncology Study. Journal of Clinical Oncology, 1998, 16(10): 3295-3301

7.       Soula G, Puccia J, Fieschi D, Bernard JL, LeBoeuf C, Fieschi M. Impact of the TOP-FORUM hypermedia system in a pediatric oncology care unit. Studies in Health Technology and Informatics, 1998, 52(2): 809-813

8.       Bouffet E, Doz F, Demaille MC, Tron P, Roche H, Plantaz D, Thyss A, Stephan JL, Lejars O, Sariban E, Buclon M, Zucker JM, Brunat-Mentigny M, Bernard JL, Gentet JC. Improving survival in recurrent medulloblastoma - Earlier detection, better treatment or still an impasse. British Journal of Cancer, 1998, 77(8): 1321-1326

9.       Michon JM, Hartmann O, Bouffet E, Meresse V, Coze C, Rubie H, Bordigoni P, Cattiaux E, Ward N, Bernard JL, Lemerle J, Zucker JM, Philip T. An open-label, multicenter, randomized Phase-2 study of recombinant human granulocyte-colony-stimulating factor (Filgrastim) as an adjunct to combination chemotherapy in pediatric-patients with metastatic neuroblastoma. European Journal of Cancer, 1998, 34(7): 1063-1069

10.     Leca F, Marchiset-Leca D, Galeani A, Noble A, Catalin J. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: Clinical application using only one blood sample. Anticancer Drugs, 1998, 9(6): 503-509

11.     Rubie H, Michon J, Plantaz D, Peyroulet MC, Coze C, Frappaz D, Chastagner P, Baranzelli MC, Mechinaud F, Boutard P, Lutz P, Perel Y, Leverger G, DeLumley L, Millot F, Stephan JL, Margueritte G, Hartmann O. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). British Journal of Cancer, 1998, 77(12): 2310-2317

12.     Oliva L, Beaugé F, Guitaoui M, Choquart D, Montet AM, Montet JC. Ursodeoxycholate alleviates alcoholic fatty liver damage in rats. Alcoholism, Clinical and Experimental Research, 1998, 22(7): 1538-1543

13.     Tabouy L, Zamora A, Oliva L, Montet AM, Beaugé F, Montet JC. Ursodeoxycholic acid protects against ethanol-induced liver mitochondrial injury. Life Sciences, 1998, 63(25): 2259-2270

14.     Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, Bernard JL. Clinical features of Behcet's disease in children: An international collaborative study of 86 cases. Journal of Pediatrics, 1998, 132(4): 721-725

1997

1.       Guillet P, Monjanel-Mouterde S, Nicoara A, Duffaud F, Lacarelle B, Bagarry-Liegy D, Durand A, Catalin J, Favre R. A bayesian dosing method for carboplatin given by continuous infusion for 120 hours. Cancer Chemotherapy Phamacology, 1997, 40(2): 143-149

2.       Balandraud-Pieri N, Queneau PE, Caroli-Bosc FX, Bertault-Pérès P, Montet AM, Durand A, Montet JC. Effets of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats. Drug Metabolism and Disposition, 1997, 25(8): 912-916

3.       Evene E, Chatelut E, Tranchand B, Canal P, Lochon I, liadis A, Ardiet C. Estimation bayésienne des paramètres pharmacocinétiques de l'étoposide. Bulletin du Cancer, 1997, 84(7): 699-703

4.       Namouni F, Doz F, Tanguy ML, Quintana E, Michon J, Pacquement H, Bouffe E, Gentet JC, Plantaz D, Lutz P, Vannier JP, Validire P, Neuenschwander S, Desjardins L, Zucke JM. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a hematopoietic stem-cell rescue in patients with high-risk retinoblastoma - A Sfop and Sfgm Study. European Journal of Cancer, 1997, 33(14): 2368-2375

5.       Monti H, Tiliacos N, Faure R, Aubert C. 8-a-Hydroxycaryophylene, T-muurolol and a-cadinol from Copaïba oil. Pharmaceutical and Pharmacological Letters, 1997, 8(1): 41-42

6.       Gentet JC, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, DeLumley L, Pacquement H, Schmitt C, Sariban E, Bernard JL, Kalifa C. Ifosfamide and etoposide in childhood osteosarcoma. A SFOP Phase II study. European Journal of Cancer, 1997, 33(2): 232-237

7.       Marchetti MN, Sampol E, Bun H, Scoma H, Lacarelle B, Durand A. In vitro metabolism of three major isomers of retinoic acid in rats. Intersex and interstrain comparison. Drug Metabolism and Disposition, 1997, 25(5): 637-646

8.       Takacs T, Lonovics J, Caroli-Bosc FX, Montet AM, Montet JC. Litholyse de contact des calculs de la voie biliaire principale. Etude chez 44 patients. Gastroenterologie Clinique et Biologique, 1997, 21(10): 655-659

9.       Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, Pearson A, Klingebiel T, Garaventa A, Kremens B, Bernard JL, Rosti G, Chauvin F. 1070 myeloablative megatherapy procedures followed by stem-cell rescue for neuroblastoma - 17 years of European experience and conclusions. European Journal of Cancer, 1997, 33(12): 2130-2135

10.     Nonnenmacher E, Hever A, Mahamoud A, Aubert C, Molnar J, Barbe J. A novel route to new dibenzo [b,f] [1,5] diazocine derivatives as chemosensitizers. Organic Preparations and Procedures International, 1997, 29(6): 711-715

11.     Salemi-Delvaux C, Aubert C, Campredon M, Guisti G, Guglielmetti R. On the photodegradation of 3-3-diphenyl-(3H)-naphtho (2,1-B) pyrane in solution. Molecular Crystals and Liquid Crystals Science and Technology. Section A., 1997, 297-298: 321-327

12.     Tran A, Yang G, Doglio A, Ticchioni M, Laffont C, Durant J, Bernard JL, Gugenheim J, Saintpaul MC, Bernard A, Rampal P, Benzaken S. Phenotyping of intrahepatic and peripheral-blood lymphocytes in patients with chronic hepatitis-C. Digestive Disease and Sciences, 1997, 42(12): 2495-2500

13.     Bun H, Monjanel-Mouterde S, Audebert C, VincentDuLaurier M, Durand A, Cano JP. Pharmacokinetics of tropatepine in healthy volunteers. Clinical Drug Investigation, 1997, 14(1): 53-60

14.     Rontani JF, Cuny P, Aubert C. Rates and mechanism of light-dependant degradation of sterols in senescent cells of phytoplankton. Journal of Photochemistry and Photobiology A: Chemistry, 1997, 111(1-3): 139-144

1996

1.       Bagarry-Liegey D, Nicoara A, Duffaud F, Guillet P, Pignon T, Catalin J, Durand A, Favre R. Adaptation individuelle de posologie du Methotrexate à haute dose (MTX-HD) en pratique clinique courante. Revue de Médecine Interne, 1996, 17(8): 689-698

2.       Figarella-Branger D, Dubois C, Chauvin P, Victor BD, Gentet JC, Rougon G. Correlation between polysialic-neural cell adhesion molecule levels in CSF and medulloblastoma outcomes. Journal of Clinical Oncology, 1996, 14(7): 2066-2072

3.       Attolini L, Gantenbein M, Villard PH, Lacarelle B, Catalin J, Bruguerolle B. Effects of different exposure to tobacco smoke intoxication on carboxyhemoglobin and hepatic enzymate activities in mice. Journal of Pharmacological and Toxicological Methods, 1996, 35(4): 211-215

4.       Disdier B, Bun H, Placidi M, Durand A. Excretion of oral 9-cis-retinoic acid in the rat. Drug Metabolism and Disposition, 1996, 24(11): 1279-1281

5.       Seree E, Villard PH, Re JL, DeMéo M, Lacarelle B, Attolini L, Duménil G, Catalin J, Durand A, Barra Y. High inductibility of mouse renal CYP2E1 gene by tobacco smoke and its possible effect on DNA single strand breaks. Biochemical and Biophysical Research Communications, 1996, 219(2): 429-434

6.       Evrard A, Vian L, Aubert C, Cano JP. An in vitro nucleoside anlog screening method for cancer gene-therapy. Cell Biology and Toxicology, 1996, 12(4-6): 345-350

7.       Donadieu J, Thomas C, Brugières L, Herbelin C, Bertrand Y, Schmitt C, Robert A, Fagnoux C, Emile JF, Micheau M, Gentet JC, Plantaz D, Teillac-Hamel D, Edan C, Democq F, Mechinaud F, Leverger G. Multicentre retrospective survey of Langerhan's cell histiocytosis: 348 cases observed between 1983 and 1993. Archives of Disease in Childhood, 1996, 75(1): 17-24

8.       Claret L, Iliadis A. Non-parametric density estimation applied to population pharmacokinetics. Mathematical Biosciences, 1996, 133(1): 51-68

9.       Ciccolini J, Monjanel-Mouterde S, Catalin J, Favre R, Durand A. Paramètres pharmacocinétiques de population du Methotrexate administré à haute dose: Application en pratique clinique de routine. Journal de Pharmacie Clinique, 1996, 15(1): 34-40

10.     Iliadis A, Launay-Iliadis MC, Lucas C, Fety R, Lokiec F, Tranchand B, Milano G. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: A french cancer center multicentric study. European Journal of Cancer and Clinical Oncology, 1996, 32A(3): 455-460

11.     Disdier B, Bun H, Catalin J, Durand A. Simultaneous determination of all-trans-, 13-cis, 9-cis-retinoic acid and their 4-oxo-metabolites in plasma by high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Applications, 1996, 683(2): 143-154

12.     Sennoune S, Iliadis A, Bonneton J, Barra Y, Genton P, Mesdjian E. Steady-state pharmacokinetics of Carbamazepine-Phenobarbital interaction in patients with epilepsy. Biopharmaceutics Drug Disposition, 1996, 17(2): 155-164

13.     Guise S, Braguer D, Martin N, Catalin J, Gentet JC, Briand C. Suivi cellulaire en oncologie pédiatrique de l'action du paclitaxel en corrélation avec sa pharmacocinétique. Journal de Pharmacie Clinique, 1996, 15(ns): 88-89

14.     Moretto C, Darque A, Revel G, Bun H, Cornet M. Syndrome malin des neuroleptiques à symptomatologie incomplète: Description d'un cas clinique. Journal de Pharmacie Clinique, 1996, 15(3): 243-245

15.     Mesdjian E, Zamora AJ, Montet AM, Bonneton J, Guitaoui M, Genton P, Montet JC. Ursodeoxycholate improves hepatobiliary dysfunction induced by valproate-carbamazepine treatment in the rat. Life Sciences, 1996, 59(13): 1069-1079

1995

1.       Aubert C, Rontani JF. Characterization of 1,3-dioxolanes upon positive-ion chemical ionisation. Rapid Communication in Mass Spectrometry, 1995, 9(5): 405-407

2.       Sampol E, Lacarelle B, Rajaonarison JF, Catalin J, Durand A. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. British Journal of Clinical Pharmacology, 1995, 40(1): 83-86

3.       Guitaoui M, Montet AM, Takacs T, Montet JC. Contact solvents for common bile duct stones. Study in an in vitro system. Liver, 1995, 15(5): 247-252

4.       Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A, Favre R. Dosage adjustment of high-dose methotrexate using bayesian estimation: A comparative study on two different concentrations at the end of 8-H infusions. Therapeutic Drug Monitoring, 1995, 17(5): 471-478

5.       Doz F, Neuenschwander S, Plantaz D, Courbon B, Courbon JC, Gentet JC, Bouffet E, Mosseri V, Vannier JP, Desjardins L, Vielh P, Zucker JM. Etoposide and carboplatin in retinoblastoma: A study by the Soçiété Française d'Oncologie Pédiatrique. Journal of Clinical Oncology, 1995, 13(4): 902-909

6.       Leguellec C, Lacarelle B, Villard PH, Point-Scoma H, Catalin J, Durand A. Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: Effect of different drugs. Anesthesia Analgesia, 1995, 81(4): 855-861

7.       Takacs T, Montet JC. In vitro dissolution of cholesterol biliary stones. Gut, 1995, 37(1): 157-158

8.       Sampol E, Lacarelle B, Augier P, Point-Scoma H, Covo J, Catalin J, Durand A. Inter individual variability of CYP2B subfamily in rat: Methodological consequences. Cell Biology and Toxicology, 1995, 11(3-4): 198

9.       Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoïd arthristis. Journal of Rheumatology, 1995, 22(5): 844-849

10.     Marchiset-Leca D, Leca F, Galeani A, Noble A, Iliadis A. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans. Cancer Chemotherapy and Pharmacology, 1995, 36(3): 233-238

11.     Marchiset-Leca D, Leca F, Galeani A, Noble A, Catalin J. Pharmacokinetic and metabolism of pirarubicin in humans: Correlation with pharmacodynamics. Cancer Chemotherapy and Pharmacology, 1995, 36(3): 239-243

12.     Launay-Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulid-Aissa D, Marty M, Clavel M, Aapro M, LeBail N, Iliadis A. Population pharmacokinetics of docetaxel (Taxotere) during phase I sudies using NONlinear Mixed Effect Modeling (NONMEM) and Non Parametric Maximum Likelihood (NPML). Cancer Chemotherapy and Pharmacology, 1995, 37(1-2): 47-54

13.     Gentet JC, Bouffet E, Doz F, Tron P, Tron H, Roche H, Frappaz D, Thiss A, Plantaz D, Genitori, Lapras C, Ponvert D, Carrie C, Raybaud C, Brunat-Mentigny M, Choux M, Philip T, Zucker JM, Bernard JL. Preirradiation chemotherapy including "8 Drugs in 1 Day" regimen and high-dose methotrexate in medulloblastoma: Results of the M7 French Cooperative Protocol. Journal of Neurosurgery, 1995, 82(4): 608-614

14.     Guys JM, Delarue A, Lehors-Albouze H, Esposito C, Louis-Borrione C, Portas M, Gentet JC. Videosurgery in oncological pediatrics. Pediatric Surgery International, 1995, 10(5-6): 371-373

 

 

 

OUVRAGES

Macheras P, Iliadis A. Modeling in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics. Homogeneous and Heterogeneous Approaches. New York: Spinger Verlag, 2005.

Series: Interdisciplinary Applied Mathematics, Vol. 30

2006, XX, 442 p. 131 illus., Hardcover

ISBN: 0-387-28178-9

About this book

The state of the art in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Modeling is presented in this book. It shows how advanced physical and mathematical methods can expand classical models in order to cover heterogeneous drug-biological processes and therapeutic effects in the body. The book is divided into four parts; the first deals with the fundamental principles of fractals, diffusion and nonlinear dynamics; the second with drug dissolution, release, and absorption; the third with empirical, compartmental, and stochastic pharmacokinetic models, and the fourth mainly with nonclassical aspects of pharmacodynamics. The classical models that have relevance and application to these sciences are also considered throughout. Many examples are used to illustrate the intrinsic complexity of drug administration related phenomena in the human, justifying the use of advanced modeling methods. This timely and useful book will appeal to graduate students and researchers in pharmacology, pharmaceutical sciences, bioengineering, and physiology.

 

Proposed by Pr. A.S. Fokas (Cambridge, UK), this book was awarded at 28/12/2007 by the National Academy of Sciences of Athens, Athens

 

 

EVRARD A, CICCOLINI J, CUQ P, CANO JP. Enzyme/product systems : Thymidine phosphorylase/5"-deoxy-5-fluorouridine. In : Suicide Gene Therapy : Methods and Protocols, C.J. Springer, Eds. Humana Press, 2004: 263-278 (chapitre).

ILIADIS A. "Notions de pharmacocinétique". In : Toxicologie, A. Viala and A. Botta, Eds. Paris : Lavoisier 2005: 97-107 (chapitre).

BUN H. "Critères de validité d'une méthode d'analyse" In : Toxicologie, A. Viala and A. Botta, Eds. Paris : Lavoisier 2005: 481-484 (chapitre).

VIALA A, AUBERT C. "Anxiolytiques" In : Toxicologie, A. Viala and A. Botta, Eds. Paris : Lavoisier 2005: 675-688 (chapitre).

VIALA A, AUBERT C. "Morphine, dérivés et morphinomimétiques" In : Toxicologie, A. Viala and A. Botta, Eds. Paris : Lavoisier 2005: 741-766 (chapitre).

VERTZONI M, NICOLAIDES E, SYMILLIDES M, REPPAS C, ILIADIS A. "Orally administered drug products : Dissolution data analysis with a view to in vitro-in vivo correlation," in Pharmaceutical Dissolution Testing. J. Dressman, J. Kramer and J.B. Dressman, Eds. Oxford : Taylor and Francis 2005: 229-249 (chapitre).

RONTANI F, AUBERT C. New Advances In Analytical Chemistry. Harwood Academic Publishers, Amsterdam, 2000; 207-252.

 

 

 

CONFERENCES INVITEES

1.       Iliadis A. Modeling drug dynamics in clinical settings. In: Défis actuels des mathématiques en médecine et biologie du cancer: Modélisation et analyse mathématique, Marseille, 23-27 february 2009

2.       Iliadis A. Nouveaux modèles adaptatifs PK/PD en oncologie. In: 12èmes journées du GPCO, Marseille, 25-26 september 2008

3.       Iliadis A. Optimisation de la chimiothérapie du cancer du sein métastatique à l'aide d'un modèle partiellement mécanistique de la toxicité hématologique: L'essai MODEL 1. In: 3èmes Journées Scientifiques du CLARA, Lyon, Cancéropôle Lyon, 18-19 march 2008

4.       Iliadis A. Pharmacokinetics and dosage adjustment of Sirolimus in clinical practice. In: Contemporary aspects of Sirolimus therapy, Paphos, Cyprus, 21 april 2007

5.       Iliadis A. Dose measures in cancer medicine. In: 13th Panhellenic Pharmaceutical Congress, Athens, Greece, 12-14 may 2007

6.       Iliadis A. Modelling heterogeneity in cyclosporine pharmacokinetics. In: Workshop on Cancer Modelling and Therapeutic Innovation: From Theory to Clinic, Lyon, 27-28 september 2006

7.       Barbolosi D. Mathematical modelling optimises the Docetaxel - Epirubicin combination in a phase I trial. In: Workshop on Cancer Modelling and Therapeutic Innovation: From Theory to Clinic, Lyon, 27-28 september 2006

8.       Bun H, Bun SS. Anticorps monoclonaux: applications thérapeutiques. In: Cambodge, Santé 2001, Phnom Penh, Cambodge, 13-17 november 2001

9.       Iliadis A. Optimal control and drug variability. In: 13èmes Entretiens du Centre Jacques Cartier. Colloque n°7: Variabilité de la Thérapeutique Médicamenteuse. Décrire et Estimer pour Prédire et Contrôler, Montréal, 4-6 october 2000

10.     Bun H. Evaluation de la qualité des médicaments. In: IVème Journées Médico-Pharmaceutiques, Phnom Penh, Cambodge, 7-8 august 2000

11.     Reynier JP, Bun H, Piccerelle P. Innovation pharmaceutique du XXème siècle. In: Cambodge, Santé 2002 (n°2), Phnom Penh, Cambodge, 15-19 november 1999

12.     Montet JC. Le traitement dissolvant de la lithiasse de la voie biliaire principale. In: Association Française de Chirurgie, Paris, 8 october 1999

13.     Bun H. Thérapie génique en cancérologie. In: Cambodge, Santé 2002 (n°2), Phnom Penh, Cambodge, 15-19 november 1999

14.     Iliadis A. Population methods. In: The Population Approach: Measuring and Managing Variability in Pharmacokinetics and Drug Effects, Montreal, 21-22 october 1998

15.     Catalin J. Les anticancéreux. In: Cambodge, Santé 2000, Phnom Penh, Cambodge, 23-27 november 1998

16.     Bun H, Disdier B. Médicaments à status particulier: La clozapine. Etudes in vivo et in vitro. In: Cambodge, Santé 2000, Phnom Penh, Cambodge, 23-27 november 1998

17.     Bun H, Aubert C. Identification et dosage de divers types xénobiotiques dans différentes matrices. In: Cambodge, Santé 2000, Phnom Penh, Cambodge, 23-27 november 1998

18.     Iliadis A. Population pharmacokinetics: Parametric vs. Nomparametric Approaches. In: Satellite Meeting on Non-Parametric and Semi-parametric methods in population PK/PD data analysis, Geneva, 12-14 february 1997

19.     Iliadis A. Population pharmacokinetics: Parametric vs. Nomparametric Approaches. In: Sixth Annual Meeting of the German Society for Clinical Pharmacology, Dresden, 5-7 september 1996

20.     Iliadis A. Control of bilinear systems in biology. In: Nonlinear dynamics, chaos, fractals and fractal kinetics in drug reseaech. A Satellite of the 6th European Congress on Biopharmaceutics and Pharmacokinetics, Athens, 21 april 1996

21.     Bun H. Bioéquivalence des formes pharmaceutiques. In: Ministère de la Santé, Phnom Penh, Cambodge, 20 january 1996

22.     Bun H. Différentes techniques analytiques pour identifier et/ou doser les médicaments. In: Laboratoire du Contrôle des Médicaments, Phnom Penh, Cambodge, 13 january 1996

 

 

 

COMMUNICATIONS

2009

0.       Frances N, Claret L, Schaedeli-Stark F, Bruno R, Iliadis A. Modeling of longitudinal tumor size data in clinical oncology studies of drugs in combination. In: 18th PAGE Meeting, Marseille, 2008

2008

1.       Frances N, Claret L, Schaedeli-Stark F, Bruno R, Iliadis A. Modeling of longitudinal tumor size data in clinical oncology studies of drugs in combination. In: 18th PAGE Meeting, Marseille, 2008

2007

1.       Iliadis A. Monitoring des toxicités hématologiques et optimisation de l'efficacité au cours d'une chimiothérapie anticancéreuse à l'aide d'un modèle dynamique. In: Mathématiques et Cancer, Marseille: CMI, FRUMAM, 2007

2.       You B, Meille C, Barbolosi D, Tranchand B, Guitton J, Rioufol C, Iliadis A, Freyer G. A mechanistic model predicting hematopoiesis and tumor growth to optimize docetaxel + epirubicin (ET) administration in metastatic breast cancer (MBC): Phase I trial. In: ASCO Annual Meeting, Chicago, USA, 2007

3.       Meille C, Favier L, Coudert B, Barbolosi D, Iliadis A, Biville F, Garnier J, Ferri-Dessens R. Retrospective analysis of data from a phase I trial with a new adaptive method. In: ASCO Annual Meeting, Chicago, USA, 2007

4.       Kyriakides G, Meille C, Iliadis A, Zografidis A. Dosage adjustment of sirolimus given in combination with mycophenolate mofetil in de novo transplant patients. In: ESOT, 13th Congress of the European Society for Organ Transplantation, Prague, Czech Republic, 2007

2006

1.       Montet J, Parquet M, Dallest J, Desobry A, Lindheimer M, Montet A. L'hydrophobie des sels biliaires module la toxicité de la ciclosporine. In: Journées Francophones de Pathologie Digestive, Paris, 18-22 mars 2006, 2006

2.       Montet J, Lindheimer M, Appel J, Montet A. Quels sont les déterminants de la sécrétion biliaire du cholestérol? Effet de la structure des sels biliaires. In: Journées Francophones de Pathologie Digestive, Paris, 18-22 mars 2005, 2006

3.       Meille C. Nouvelle méthode de planification adaptive des essais de phase I en cancérologie pédiatrique. In: Société de pédiatrie, Lyon, 14-17 juin 2006, 2006

4.       Gauchon A, Andre N, Rome A, Coze C, Lautraite C, Dubus J, Bernard J. Stratégie de prise en charge de contage tuberculeux dans un service d'Oncologie Pédiatrique. In: Congrès des Sociétés de Pédiatrie, Lyon, 2006

5.       Fabre A, Andre N, Jacob T, Dore E, Rome A, Coze C, Montet J, Michel G, Mundler O. Intérêt du PET-Scan dans l'évaluation des masses résiduelles en Oncologie Pédiatrique. In: Congrès des Sociétés de Pédiatrie, Lyon, 2006

6.       Salas S, Mercier C, Ciccolini J, Pourroy B, Dupuis C, Baciuchka-Palmaro M, Durand A, Duffaud F, Tranchand B, Favre R. Population pharmacokinetic of total cisplatinum: application to adaptative dosing with feedback in testicular cancer patient. In: ASCO Annual Meeting Proceedings, Atlanta, USA, 2006

7.       Rubie H, Chishlom J, Defachelles A, Morland B, Munzer C, Valteau-Couanet D, Hargrave D, Bergeron C, Coze C, Djafari L, Vassal G. Temozolomide phase II study in children with relapsing refractory high-risk neuroblastoma. In: ASCO Annual Meeting, 2006

8.       Mercier C, Yang C, Ciccolini J, Evrard A, Boyer J, Boyer A, Blesius A, Dahan L, Richard K, Seitz J, Lacarelle B, Favre R. Determination of uracil/UH2 ratio as a potential surrogate for DPD status in cancer patients presenting with severe toxicities during fluoropyrimidine treatment. In: ASCO Annual Meeting proceedings, Atlanta, USA, 2006

9.       Fanciullino R, Giacometti S, Aubert C, Fina F, Piccerelle P. Development of a stealth liposomal formulation of d-Ino as 5-FU modulator: in vitro and in vivo study. In: AACR 97th Meeting, Washington DC, USA, March-April 2006

10.     Ea S, Bun S, Aubert C, Siv V, Bun H. Etudes métabolique et cytotoxique de l'haphamine issue des plantes naturelles. In: Cambodge Santé, Phnom Penh, Cambodge, 2006

11.     Dupuis C, Mercier C, Salas S, Yang C, Deville J, Balti M, Ciccolini J, Iliadis A, Baciuchka M, Duffaud F, Favre R. Implication of clinical and paraclinical covariates in the pharmacokinetics of high dose MTX (HD-MTX) in patients with osteosarcomas. In: ASCO Annual Meeting Proceedings, Atlanta, USA, 2006

12.     Cojean N, Michon J, Schmitt C, Coze C, Plantaz D, Lumley LD, Nelken B, Corradini N, Patte C. Ovarien involvement in childhood B-cell non-Hodgkin's lymphom (B-NHL): The SFOP LMB experience. In: SIOP XXXV Meeting, september 2004, PD009, 2006

13.     Bory S, Chhay K, Pin Y, Ty S, Im C, Nam N, Tea K, Tea S, Bun H. Evalutation de la qualité des médicaments fabriqués au Cambodge. In: VIIème Journées de Médecine et de Pharmacie, Phnom Penh, Cambodge, 2006

14.     Andre N, Patte C, Bergeron C, Landmann-Parker J, Michon J, Perel Y, Vannier J, Coze C. Renall cell carcinoma in children. Prognostic factors and outcome. A SFOP retrospective study. In: SIOP XXXV Meeting, october 2003, PF044, Cairo, 2006

15.     Andre N, Kababri ME, Coze C, Gentet J, Rome A, Bernard J. Safety and efficacy of pegfilgrastim (Neulasta) in teenagers patients with cancer receiving myelosuppressive chemotherapy. In: SIOP XXXVIII Meeting, september 2006, Geneve, 2006

2005

1.       Salas S, Tuzzolino F, Duffaud F, Mercier C, Cannone P, Favre R. Enquête sur l'utilisation de la Kétamine en soins palliatifs dans la région Provence Alpes Côte d'Azur: Résultats préliminaires portants sur 23 médecins impliqués dans les soins palliatifs. In: Poster SFASP, 2005

2.       Meille C. Planification adaptative des Essais de Phase I en Cancérologie. In: Société Française des Cancers de l'Enfant (SFCE), Marseille, 2005

3.       Meille C. New phase I adaptative trial escalation in cancerology. In: 5th International Meeting: Statistical Methods in Biopharmacy. Statistical Innovations in Clinical Trials, Paris, 26-27 septembre, 2005

4.       Meille C. Optimal population PK design & Boostrap, randomization and mixture model tests in NOMMEN. In: WORKSHOP, Marseille, 10-11 octobre 2005

5.       Kababri ME, Andre N, Rome A, Gentet J, Coze C, Bernard J. Utilisation du Neulasta en oncologie pédiatrique. In: Congres National de la Société Française de Pédiatrii, Paris, juin 2005

6.       Fanciullino R, Giacometti S, Martin P. Developpement d'un liposome furtif de la dIno, biomodulateur de l'activité du 5 FU. In: Eurocancer, juin 2005, Paris, 2005

7.       Demarquay J, Caroli-Bosc F, Montet A, Paul MS, Tran A, Montet J. L'acide ursodésoxycholique réduit l'hépatotoxicité du méthotrexate chez le rat. In: Journées Francophones de Pathologie Digestive, Paris 2-6 avril 2005, 2005

2004

1.       Salas S, Duffaud F, Baggary D, Digue L, Mercier C, Favre R. Evaluation et prise en charge thérapeutique des plaies cancéreuses: Impact sur la qualité de vie des patients. In: AFSSAPS, Besançon, juin, 2004

2.       Montet J, Parquet M, Aubert C, Montet A. Le tauro B-muricholate, un agent hépatoprotecteur, résiste au métabolisme hépatique. In: Journées Francophones de Pathologie Digestive, Paris, 3-7 avril, 2004

3.       Valteau-Couanet D, Michon J, Perel Y, Bergeron C, Rubie H, Coze C, Rodary C, Hartmann O. Results of NB SFOP protocol in children > 1 year with a stage 4 neuroblastoma. In: SIOP XXXV Meeting, september 2004, 0137, Oslo, 2004

4.       Rubie H, Defachelles A, Coze C, Hartmann O, Djazouli K, Auvrignon A, Schell M, Boutard P, Couillault G, Kanold J, Piguet C, Munzer C, Vassal G. Temozolomide phase II study in children with relapsing/refractory high-risk neuroblastoma. In: SIOP XXXV Meeting, september 2004, PD067, 2004

5.       Patte C, Orbach D, Rubie H, Edan, Pichon F, Schmitt C, Auvrignon A, Coze C, Frappaz D, Baranzelli M. Treatment strategy for extracranial secreting germ cell tumor adapted to stage and AFP level. Updated results of the Cisplatinum based protocol TGM95 of the SFOP. In: SIOP XXXV Meetin, september 2004, 0132, Oslo, 2004

6.       Leahy M, Blay J, Verweeij J, Cesne AL, Duffaud F, Hogendoorn P, Balincourt CD, Evrard V. EORTC 62011: phase II trial of Brostallicin for soft tissue sarcoma. In: ESMO 2004, Budapest, octobre, 2004

7.       Fischel JL, Formento P, Renée N, Ciccolini J, Etienne MC, Schneider M, Milano G. Experimental arguments for a better understanding of hand-foot syndrome under capecitabine. In: AACR 95th Meeting, Orlando FL, USA, March 25-31 2004

8.       Fanciullino R, Giacometti S, Aubert C, Piccerelle P, Ciccolini J. Development of a new liposomal formulation of d-Ino as 5-FU modulator: In vitro and in vivo study. In: AACR 95th Meeting, Orlando FL, USA, March 25-31 2004

9.       Ea S, Bun SS, Siv C, Bun H. Etudes pharmacocinétique et antiparasitaire de la santonine. In: Cambodge Santé 2004, Phnom Penh, Cambodge, 18-24 février 2004

10.     Duffaud F, Cesne AL, Ray-Coquard I, Bompas E, Assi K, Berthaud P, Ducimetiere F, Blay J. Erythropoietin for the treatment of the anemia of patients with advanced Gastro Intestinal Stromal Tumors (GIST) receiving imatinib. In: American Society of Clinical Oncology, New Orleans, juin 2004

11.     Chou M, Aubert C, Bun H, Tea S. Techniques d'identification et de dosage des drogues dans les milieux biologiques. In: Cambodge Santé, Phnom Penh, Cambodge, 2004

12.     Cannone P, Dany L, Dudoit E, Duffaud F, Favre R. Patients et médecins face à la chimiothéraphie. In: VIIe International Conference on Social Representations, Guadelajara, Mexique, septembre 2004

13.     Bun S, Ea S, Chou M. Etude de la qualité du médicament. In: Cambodge Santé 2004, Phnom Penh, Cambodge, 2004

14.     Blay JY, Berthaud P, Perol D, Ray-Coquard I, Bui B, Duffaud F, Braud AC, Rios M, Coindre JM, Ducimetiere F, LeCesne A. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. In: American Society of Clinical Oncology (ASCO), New Orleans, Juin 2004

15.     Bergeron C, Gomez F, Pacquement H, Perel Y, Coze C, Mechinaud F, Gandemer V, Vannier J, Demeocq F, Schmitt C, Couillault G, Lumley Ld, Leverger G, Baruchel A, Berger C, Lejars O, Pautard B, Patte C. Treatment of childhood T lymphoblastic lymphoma (TLL). Results of the SFOP LMT96. In: SIOP XXXV Meeting, september 2004, PC004, 2004

2003

1.       Bun SS, Ancolio C, Michel G, Martin N, Gensollen S, Bongrand M, Timon-David P. Allergie au latex: constitution d'un set de dispositifs médicaux "latex free". In: Congrès Hopipharm, Toulouse, 2003

2.       Monjanel-Mouterde S, Ciccolini J, Duffaud F, Lejeune C, Lacarelle B, Favre R, Durand A. Bayesian population pharmacokinetics: application to adaptive control with feedback in cancer patients. In: AACR 94 th Meeting, Washington DC, USA, March 2003

3.       Mercier C, Tranchand B, Vassal G. Population pharmacokinetics of CPT-11 and its main metabolites in children: A nommen and xpose covariates analysis. In: ASCO annual meeting, Chicago, USA, 2003

4.       Leahy M, Blay J, Werweij J, Cesne AL, Duffaud F, Hogendoorn P, Balincourt CD, Evrard V. EORTC 62011: phase II trial of Brostallicin for soft tissue sarcoma. In: ECCO 2003, Copenhagen, octobre, 2003

5.       Kim LE, Bun H. Les interactions médicamenteuses d'ordre pharmococinétique. In: Cambodge Santé, Phnom Pen, Cambodge, 2003

6.       Gaspar N, Hartmann O, Munzer C, Bergeron C, Millot F, Cousin-Lafay L, Babin-Boilletot A, Blouin P, Pajot C, Coze C. Neuroblastoma in adolescents. In: SIP XXXV Meeting, October 2003, O030, Cairo, 2003

7.       Duffaud F, Borner M, Chollet P, Vermorken J, Bonneterre M, Rolland F, Dittrich C, Baron B, Lacombe D. For the EORTC-New drug development Group/New drug development program. Phase II study of NX211 (liposomal lurtotecan) given as an infusion over 30 minutes on days 1 and 8 every 3 weeks with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck with target lesion within previously irradiated fields or outside previously irradiated fields. In: American Society of Clinical Oncology (ASCO), Chicago, Mai 2003

8.       Bun SS, Giacometti S, Ciccolini J, Bun H, Aubert C. Biliary excretion of paclitaxel (Taxol) and its metabolites in guinea pigs. In: AACR 94 th Meeting, Washington DC, USA, March 2003

9.       Bun H, Bun SS. Interactions médicamenteuses: études in vitro et in vivo. In: Cambodge Santé, Phnom Penh, Cambodge, 2003

2002

1.       Bun SS, Ancolio C, Zuccolani M, Tehhani E, Ragon A. Evaluation de la formation en stérilisation du personnel de l'Assistance Publique des Hôpitaux de Marseille. In: 12ème Journées EURO PHARMAT, Vichy, 15-17 octobre 2002

2.       Bun SS, Ancolio C, Zuccolani M, Tehhani E, Ragon A. Gestion et suivi des non-conformités dans une unité de stérilisation. In: 24 ème Journées Nationales d'Etudes sur la stérilisation, CHFH, Lille, 20-21 Mars 2002

3.       Bun SS, Ancolio C, Passarelli S, François N, Grandgeorge E, Tehhani E, Ragon A. Stérilisation des dispositifs médicaux et médecine humanitaire: utilisation de la "cocotte-minute". In: 18ème Journées Nationales d'Informations des Pharmaciens Hospitaliers, SNPHPU, Aix-en-Provence, 18-20 septembre 2002

4.       Ancolio C, Bun SS, Zuccolani M, Tehhani E, Ragon A. Mise en conformité de la stérilisation des dispositifs médicaux des cabinets dentaires du centre pénitentiare de Marseille. In: 24ème Journées Nationales d'Etudes sur la stérilisation, CEFH, Lille, 20-21 Mars 2002

5.       Valteau-Couanet D, Michon J, Perel Y, Bergeron C, Rubie H, Coze C, Rodary C, Hartmann O. Results of NB 97 SFOP protocol in children over I year with a stage 4 neuroblastoma. In: Advances in Neuroblastoma Research, Paris, June 2002, CO15 And SIOP XXXIV Meeting, september 2002, Porto, 2002

6.       Plantaz D, Michon J, Coze C, Valteau-Couanet D, Perel Y, Leverger G, Bergeron C, Thomas C, Chastagner P, Munzer C, Rubie H. Dumbbell localised neuroblastoma. In: Advances in Neuroblastoma Research, Paris, June 2002, CO4 And SIOP XXXIV Meeting, september 2002, Porto, 2002

7.       Patte C, Auperin A, Bergeron C, Coze C, Leverger G, Robert A, Schmitt C, Bachurel A, Hartmann O, Michon J. CNS involvement in B-cell malignancies: description and prognostic value-Experience of the SFOP LMB89 study. In: SIOP XXXIV Meeting, september 2002, CO032, Porto, 2002

8.       Michalowski M, Rubie H, Munzer C, Michon J, Perel Y, Bergeron C, Coze C, Thomas C, Valteau-Couanet D, Guitard J, Guys J, Piolat C, Plantaz D. Neonatal localized neuroblastoma. In: Advances in Neuroblastoma Research, Paris, June 2002, PC42 And SIOP XXXIV Meeting, september 2002, Porto, 2002

9.       Laprie A, Coze C, Valteau-Couanet D, Couturier J, Plantaz D, Schleiermacher G, Bernard J, Chastagner P, Bergeron C, Defachelles A, Combaret V, Munzer C, Rubie H. Localized neuroblastoma and MYCN amplification: improved survival with high-dose chemotherapy and locoregional irradiation. In: Advances in Neuroblastoma Research, Paris, June 2002, CO13 And SIOP XXXIV Meeting, september 2002, Porto, 2002

10.     Laprie A, Coze C, Valteau-Couanet D, Couturier J, Plantaz D, Schleiermacher G, Bernard J, Chastagner P, Bergeron C, Combaret A, Patte C, Munzer C, Rubie H. High-dose chemotherapy followed by locoregional irradiation improves the outcome of children with localized neuroblastoma and MYCN amplification. In: ASCO Meeting, Orlando, May 2002

11.     Hapke G, Cao S, Ciccolini J, Evrad A, Durrani F, Rustum YM. High levels of thymidine phosphorylase diminish synergistic activity of irinotecan/CPT-11 followed by FU in human colon xenografts LS174/TP. In: ASCO 38th Meeting, Orlando FLA, USA, April 18-22 2002

12.     Claret L, Macheras P, Simon N, Iliadis A. A stochartic model for drugs exhibiting leterogeneous pharmacokinetics. In: 11th population Approach Group in European Meeting, Paris, June 6-7 2002

13.     Bun SS, Calabro S, Cabrol P, Ausias N, Piquet P, Lambert M, Reynier JP. Pharmacoeconomic evaluation of carotid endarterectomy. In: 7th Congress of EAHP, Vienne, 20-21 Mars 2002

14.     Bun SS, Ancolio C, Tehhani E, Ragon A. French quality assurance to prevent the risk of variant Creutzfeldt-Jakob transmission through contaminated medical devices. In: 7th Congress of EAHP, Vienne,  Autriche, 20-22 Mars 2002

15.     Braguer D, Carré M, André N, Carles G, Douillard S, Ciccolini J, Briand C. Involvement of microtubules and mitochondrie in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. In: AACR 93 th Meeting, San Francisco, April 5-10 2002

16.     Bezulier K, Ciccolini J, Fina S, Giacometti S, Martin PM, Milano G, Iliadis A. Real-time PCR determination of Fas/FasL expression in tumor cells exposed to fluoropyrimidines: in vitro background and clinical relevance. In: AACR 93th Meeting, San Francisco, April 6-10 2002

17.     Bergeron C, Gomez F, Pacquement H, Perel Y, Coze C, Méchinaud F, Schmitt C, Vanier J, Gandemer V, Couillault G, Leverger G, Baruchel A, Patte C. Treatment of childhood T lymphoblastic lymphoma - Results of the SFOP LMT96. In: SIOP XXXIV Meeting, september 2002, P376, publié dans Med Pediatr Oncol, 2002

18.     Barbolosi D, Ciccolini J, Iliadis A. Optimising drug regimens in chemotherapy by an efficacy-toxicity mathematical model. In: AACR 93th Meeting, San Francisco CA, USA, April 6-10 2002

19.     Baille-Albert P, Petricoul O, Fuseau F, Iliadis A. Information indexes for exploratory data analysis in population pharmacokinetics. In: 11th Population Approach Group in Europ Meeting, Paris, June 6-7 2002

2001

1.       Haro LD, Valli M, Bourdon H, Iliadis A, Hayek-Lanthois M, Aditti J. Unusual diazepam poisoning case report with one month evolution of diazepam blood levels. In: 9° Congrès de la Société Française de Toxicologie Analytique, La Cluza Haute Savoie, 2001

2.       Bezulier K, Ciccolini J, Fina F, Martin PM, Milano G, Catalin J. Etude du statut Fas/FasL au sein  de tumeurs colorectales: facteurs pronostique de réponse aux fluoropyrimidines? In: XXIème Congrès de Cancérologie / Eurocancer 2001, Paris, 3-7 Juin 2001

3.       Bezulier K, Ciccolini J, Evrard A, Cuq P, Aubert C, Cano JP, Cano J. Implication du système Fas/FasL et de la thymidine phosphorylase dans la réponse apaptique induite par la capécitabine. In: XXIème Congrès de Cancérologie / Eurocancer 2001, Paris, 3-7 Juin 2001

4.       Montet JC, Beauge F, Oliva L, Montet AM. Bile acids modulate chronic ethanol - induced hepatotoxicity in the rat. In: 8th Congress of the European Society for Biomedical Research on Alcoholism, Paris, 15-18 Septembre 2001

5.       Mercier C, Tranchand B, Vassal G. Pharmacokinetics of CPT-11 and its main metabolites in children. In: PAGE annual meeting, Salamanque, Espagne, 2001

6.       Ciccolini J, Bezulier K, Evrard A, Cuq P, Aubert C, Cano JP, Catalin J. Role of Thymidine Phosphorylase as determinant to colorectal tumor cell sensitivity to capecitabine implication of Fas in Xeloda -induced apoptosis? In: AACR 92th Meeting, New Orleans LA, USA, March 24-28 2001

7.       Bun SS, Andrieu V, Reynier JP. Formulations de gels oraux à usage pédiatrique. In: Cambodge Santé 2001, Phnom Penh, Cambodge, 13-17 Novembre 2001

2000

1.       Salmon L, Montet JC, Oddoze C, Michel BF. Hépatotoxicité de la Tacrine. Effet de l'acide ursodésoxycholique. In: XIIIème journées du GRAL, Marseille, 27-29 Janvier 2000

2.       Oliva L, Montet AM, Montet JC. L'hydrophobie des sels biliaires module al toxicité hépatique de l'éthanol. Effet protecteur de l'acide urosodésoxycholique. In: Journées Francophones de Pathologie Digestive, Nice, 18-22 Mars 2000

3.       Mercier C, Tranchand B, Vassal G. Validation d'une stratégie de prélèvement limité pour l'étude de la pharmacocinétique du CPT-11 et de ses principaux métabolites chez l'enfant et l'adolescent. In: congrès du GPCO, Nice, 2000

4.       Iliadis A. Mathématiques et Santé. In: Mathématiques et Santé, Marseille, 2000

5.       Iliadis A. Dosage adjustment. In: Introduction  to Population pharmacokinetics, Lyon, 15-17 Mai 2000

6.       Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J, Milano G. Recherche de facteurs explicatifs de la synergie entre l'oxaliplatine (LOHP) et l'association 5-fluoro-uracile (FU) et l'acide folinique (AF). In: XX° Forum de Cancérologie, Paris, 6-8 Juin 2000

7.       Ciccolini J, Cuq P, Evrard A, Pelegrin A, Aubert C, Cano JP, Catalin J. Accroissement de l'activité antitumorale du 5FU in vitro et chez l'animal xénogreffé par double modulation génétique et biochimique. In: XX° Forum de Cancérologie, Paris, 6-8 Juin 2000

8.       Ciccolini J, Cuq P, Evrard A, Aubert C, Pelegrin A, Cano JP, Catalin J. Potentialisation de l'effet anticancéreux du 5-FU in vitro et in vivo par double modulation biochimique et génétique. In: 8ème Journées du Groupe de Pharmacologie Clinique et Oncologique (GPCO), Nice, 19-20 Octobre 2000

9.       Caroli-Bosc FX, Ferrari P, Paolini O, Demarquay JF, Rampal P, Delmont JP, Montet JC. Influence de l'âge et des variations hormonales sur la motricité vésiculaire chez les sujets avec et sans lithiase. In: Journées Francophones de Pathologie Digestive, Nice, 18-22 Mars 2000

10.     Bun SS, Darque A, Vincentelli J, Roulant V, Gallais H, Gensollen S, Bongrand MC, Timon-David P. Critères de prescription des inhibiteurs non nucléosidiques de la transcriptase inverse. In: 1er Congrès  National sur l'observance thérapeutique, Nantes, 6-7 Octobre 2000

11.     Barbolosi D, Peillard L, Iliadis A. Optimisation des posologies en chimiothérapie anticancéreuse à l'aide d'un modèle mathématique. In: 8ème Journées du Groupe de Pharmacologie Clinique et Oncologique (GPCO), Nice, 19-20 Octobre 2000

12.     Rostagno P, Formento P, Ciccolini J, Fischel JI, Etienne MC, Catalin J, Milano J. Mechanisms of the synergy between oxaliplatin (LOHP) and 5-FU/folinic acid. In: AACR 91th Meeting, San Francisco CA, USA, April 1-5 2000

13.     Oliva L, Montet AM, Montet JC. L'hydrophobie des sels biliaires module la toxicité  hépatique de l'éthanol. Effet protecteur de l'acide ursodésoxycholique. In: Journée Francophones de Pathologie Digestive, Nice, 18-22 Mars 2000

14.     Montet JC, Salmon L, Caroli-Bosc FX, Demarquay JF, Montet AM, Delmont JP. L-Arginine infusion protects againts hyperammonemia and hepatic encephalopathy in cirrhotic patients with variceal haemorrhage. In: AASLD, San Diego, Mai 2000

15.     Montet JC, Iliadis A, Macheras P, Montet AM, Caroli-Bosc FX. Cyclosporin A pharmacokinetics in liver transplant recipients and its modulation  by urodeoxycholic acid. In: XVI International Bile Acid Meeting "Biology of  Bile Acids in Health and Disease", Den Haag, Netherlands. A117, 12-13 octobre 2000

16.     Iliadis A, Macheras P, Caroli-Bosc FX, Montet AM, Salmon L, Montet JC. Cyclosporin A pharmacokinetics in liver transplant recipients. Effect of ursodeoxycholic acid. In: American Gastroenterological Association, Digestive Disease Week, San Diego, 25-29 May 2000

17.     Cuq P, Evrard A, Ciccolini J, Vian L, Cano JP. Uridine phosphorylase gene transfer does not  increase the sensitivity to fluoropyrimidines of human breast cancer cells. In: AACR 91th Meeting, San Francisco, April 1-5 2000

18.     Ciccolini J, Evrard A, Cuq P, Pelegrin A, Aubert C, Cano JP, Catalin J. Enhanced antitumor activity of 5-FU in human colorectal cell line and Human xenograft by double genetic and biochemical modulation. In: AACR 91th Meeting, San Franisco CA, USA, April 1-5 2000

19.     Bun SS, Darque A, Vincentelli J, Gensollen S, Bongrand MC, Timon-David P. Prise en charge pharmaceutique des patients VIH. In: IVèmes Journées Nationales de Médecine-Pharmacie, Phnom Penh, Cambodge, 7-8 Aout 2000

1999

1.       Ciccolini J, Peillard L, Aubert C, Catalin J, Formento P, Milano G. Etude in vitro de la phosphorylation des fluoropyrimidines: application à la pharmacomodulation du 5-FU par la 2'deoxyinosine. In: XIXème Forum de Cancérologie, Paris, 31 Mai - 1er Juin 1999

2.       Caroli-Bosc FX, Legall P, Delabre B, Rampal P, Montet JC, Delmont JP. Rôle des fibrates et des inhibiteurs HMGCoA réductase dans la genèse de la lithiase vésiculaire. Etude épidémiologique dans une population non sélectionnée (Vidauban). In: Présentation aux 45ème journées de l'AFEF, Montpellier, 1er Octobre 1999

3.       Valsami G, Iliadis A, Macheras P. Nonlinear regression analysis with errors in both variables: Estimation of cooperative bibding parameters. In: 7th European Congress of Biopharmaceutics and Pharmacokinetics, Jérusalem, April 25-30 1999

4.       Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-FU and 5'-dFUR in human colorectal cells transfected with thymidine phosphorylase. In: AACR 90th Meeting, Philadelphia, USA, April 9-14 1999

5.       Ciccolini J, Peillard L, Evrard A, Cuq P, Aubert C, Catalin J. In vivo modulation of antitumor activity of 5-FU by 2'-deoxyinosine in human colorectal xenograft model. In: AACR-NCI-EORTC International conference, Washington DC, USA, November 16-19 1999

6.       Ciccolini J, Peillard L, Aubert C, Catalin J, Formento F, Milano G. Modulation of metabolism and potentiation of cytotoxic activity of 5-FU in human colorectal cell lines by 2' deoxyinosine. In: 90th Meeting AACR, Philadelphia, USA, April 9-14 1999

1998

1.       Ciccolini J, Peillard L, Aubert C, J. JC. Exploration in vitro du métabolisme des pyrimidines halogénées sur un adénocarcinome colique humain: étude de la phosphorylation du 5-FU en métabolites actifs par pharmacomodulation chimique. In: 7ème Journées du GPCO, Arcachon, 22-23 Octobre 1998

2.       Bun SS, Bun H, Aubert C, Catalin J. Etude in vitro au moyen de microsomes hépatiques humains des interactions médicamenteuses du paclitaxel. In: 7ème Journées du GPCO, Arcachon, 22-23 Octobre 1998

3.       Barbolosi D, Iliadis A. Optimisation des protocoles en chimiothérapie par l'utilisation d'un modèle mathématique efficacité-toxicité. In: 7ème Journées du GPCO, Arcachon, 1998

4.       Tabouy L, Zamora AJ, Oliva L, Montet AM, Beauge F, Montet JC. Ursodeoxycholate alleviates alcohol-induced liver mitochondrial injury. In: American Gastroenterological Association, New Orleans, Mai 1998

5.       Nguyen TD, Oliva L, Villard PH, Puyou F, Sauze C, Montet AM, Durand A, Montet JC, Lacarelle B. Effet hépatoprotecteur de l'ursodésoxycholate vis à vis de la lipoperoxydation induite par l'alcool: absence de relation avec l'expression des CYP2E1 et CYP3A1/2. In: Effet hépatoprotecteur de l'ursodésoxycholate vis à vis de la lipoperoxydation induite par l'alcool: absence de relation avec l'expression des CYP2E1 et CYP3A1/2, Paris, 24 Novembre 1998

6.       Mouaz AB, Lindheimer M, Montet JC, Montet AM, Zajac J. Interactions between tauroconjugated bile salts and model membranes. A31 P NMR study. In: Présentation au 72nd Colloid and Surface Science Symposium, Pennsylvania, USA, June 21-24 1998

7.       Montet JC, Oliva L, Tabouy L, Salmon L, Montet AM. Ursodeoxycholate alleviates ethanol-induced liver mitochondrial injury. In: Présentation au XV International Bile Acid Meeting. Bile Acids and Cholestasis, Titisee, Germany, October 12-13 1998

8.       Kalifa C, Raquin M, Bouffet E, Gentet JC, Doz F, Chastagner P, Grill J, Rialland X, Lellouch-Tubiana A. Chemotherapy without irradiation in medulloblastoma patients younger than three. A prospective study by the SFOP. In: 8th International Symposium on Pediatric Neuro-Oncology, Rome, 1998

9.       Guitaoui M, Aubert C, Montet AM, Infante R, Montet JC. Conjugation with taurine inhibits side-chain oxidation of ß muricholate in rats. In: American Gastroenterological Association, New Orleans, Mai 1998

10.     Gentet JC, Frappaz C, Pautard B, Perel Y, Kalifa C, Lumley LD, Edan C, Stephan JL, Boutard P, Couillault G, Armari C, Jimeno MT. Procarbazine in children with malignant brain stem glioma. A SFOP phase II study. Preliminary results. In: 8th International Symposium on Pediatric Neuro-Oncology, Rome, Mai 1998

11.     Gales CL, Costet N, Gentet JC, Kalifa C, Frappaz D, Edan C, Sariban E, Plantaz D, Doz F. Cross-cultural adaptation of a Health status classification in children with cancer.First results of the french adaptation of the HUI 2 and 3. In: International Symposium "Assessing Health-related quality of life in children with cancer", Niagara on the Lake, Canada, 21-25 Juin 1998

12.     Doz F, Kalifa C, Gentet JC, Frappaz D, Demaille MC, Edan C, Chastagner E, Sariban E, Plantaz D, Babin A, Zucker JM, Neuenschwander S, Carrie C, Bours D, Mosseri V. Sandwich chemotherapy followed by radiotherapy using reduced dose to the neuraxix in standard risk medulloblastoma: a SFOP Study. In: 8th International Symposium on Pediatric Neuro-Oncology, Rome, Mai 1998

13.     Disdier B, Farisse J, Lancon C, Llorca PM, Bun H, Cornet M. Plasma concentrations of clozapine and metabolites in resistant schizophrenic patients. In: American Psychiatric Association, 151st Annual Meeting, Toronto, Canada, 31 mai - 3 juin 1998

14.     Caroli-Bosc FX, Montet JC, Peten EP, emuth N, Demarquay JF, Delmont JP. Ursodeoxycholic acid improves liver and renal biological parameters in liver transplant patients treated with Neoral (cyclosporin A). In: American Gastroenterological Association, New Orleans, Mai 1998

15.     Bun H, Aubert C, Catalin J. Interspecies variability and drug interactions of clozapine metabolism microsomes. In: American Psychiatric Association, 151st Annual Meeting, Toronto, Canada, 31 Mai - 3 Juin 1998

1997

1.       Ros LD, Iliadis A, Langan CE, Ferrari L, Efthymiopoulos C, Capriati A, Knight S. Sanfetrinem Pharmacokinetics in Patients with Acute Exacerbation of chronic Bronchitis (AECB): A Bayesian Analysis. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 28 Octobre 1997

2.       Podevin P, Conti F, Chéreau C, Montet JC, Calmus Y, Poupon R. Effects of bile acids on human mixed lymphocyte reaction; a structure-activity relationship. In: European Association for the Study of Liver, Londres, Avril 1997

3.       Caroli-Bosc FX, Montet JC, Salmon L, Demarquay JF, Buckley M, Paolini O, Dumas R, Delmont. JP. Influence de la sphinctérotomie endoscopique sur la composition de la bile hépatique. In: Association Française pour l'Etude du Foie, Strasbourg, Octobre 1997

4.       Caroli-Bosc FX, Montet JC, Bargiggia S, Finker F, Staccini P, Demarquay JF, Buckley M, Dumas R, Delmont JP. Effet de la sphinctérotomie endoscopique sur la fonctionnalité de la vésicule biliaire. In: Effet de la sphinctérotomie endoscopique sur la fonctionnalité de la vésicule biliaire, Strasbourg, Octobre 1997

1996

1.       Vassal G, Doz F, Frappaz D, Gentet JC, Rubie H, Baranzelli MC, Chastagner P, Thyss A, Pein F. New drug development in pediatric oncology in France. In: XXVIIIth SIOP Annual Meeting, Octobre 1996

2.       Takacs T, Montet AM, Guitaoui M, Montet JC. Dissolution des calculs de la voie biliaire principale par des solvants de contact enrichis en diméthylsulfoxyde (DMSO). 1996

3.       Pein F, Michon J, Valteau-Couanet D, Quintana E, Vannier JP, Frappaz D, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Plantaz D, Zucker JM, Tournade MF. High dose melphalan, etoposide and carboplatin with bone marrow transplantation as consolidation therapy in high risk Wilms'tumors. In: 22nd EBMT Annual Meeting, Vienne, Mars 1996

4.       Oberlin O, Bui NB, Brunat-Mentigny M, Roche H, Mechinaud F, Gentet JC, Babin A, Bergeron C, Schmitt C, Dubousset J, Carrie C, Demeocq F, Zucker JM. Young adults with localised Ewing's sarcoma: the experience of the French Societry of Pediatric Oncology. In: Proceedings of the American Society of Clinical Oncology, Philadelphia, May 18-21 1996

5.       Oberlin O, Bui B, Brunat-Mentigny M, Gentet JC, Habrand JL, Baranzelli MC, Dubousset J, Mechinaud F, Bergeron C, Zucker JM. Prognostic factors in localised Ewing's sarcoma. In: XXVIIIth SIOP Annual Meeting, Vienne, Octobre 1996

6.       Montet JC, Oliva L, Guitaoui M, Montet AM, Beaugé F. Improvement of alcohol-induced fatty liver by ursodeoxycholate in the rat. In: Gastroenterology, San Francisco, Mai 1996

7.       Liegez DB, Nicoara A, Duffaud F, Berard H, Guillet P, Pignon P, Monjanel-Mouterde S, Volot F, Catalin J, Juin P, Zanaret M, Favre R. Silmultaneous radiochemotherapy (RT-CT) in the treatment of locally advanced head and neck cancers. In: Sixth International Congress on Anti-Cancer Treatment, Parie, 6-9 Février 1996

8.       Lejeune C, Monjanel-Mouterde S, Hadjadj DJ, Genet D, Bonnier P, Piana L, Tubiana-Mathieu N. Combination of cisplatin and carboplatin in ovarian cancer. In: 1st European Symposium on Ovarian Cancer, Lyon, 14-15 Juin 1996

9.       Lafforgue P, Monjanel-Mouterde S, Catalin J, Durand A, Acquaviva PC. A simplified approach of low-dose methotrexate clearance using population pharmacokinetic parameters in rheumatoid arthristis patients. In: 60 th American College of Rheumatology, Orlando, Floride, 18-22 Octobre 1996

10.     Kalifa C, Brunat-Mentigny M, Pacquement H, Demaille MC, Gentet JC, Schmitt C, Babin-Boilletot A. Treatment of osteosarcoma with an intensive chemotherapy regimen (OS 87 protocol). In: XXVIIIth SIOP Annual Meeting, Vienne, Octobre 1996

11.     Jouve JL, Bollini G, Legre R, Gentet JC, Panuel M, Bernard JL. Large reconstruction for malignant bone tumor in children. The alternative of vascularised fibular bone graft. In: XXVIIIth SIOP Annual Meeting, Vienne, Octobre 1996

12.     Iliadis A. Information tools used in population pharmacokinetics. In: 6 th European Congress of Biopharmaceutics and Pharmacokinetics, Athens, Greece, April 22-24 1996

13.     Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Catalin J, Bours D, Mosseri V, Pellae-Cosset B. Phase I trial of paclitaxel in 3 hours (h) infusion for children with refractory solid tumors: a SFOP study. In: 30 th ASCO Annual Meeting, Philadelphia, May 18-21 1996

14.     Catalin J, Monjanel-Mouterde S, Martin N, Blachon MF. Phase I trial of Taxol in children. Preliminary pharmacokinetic results. In: Joint UKCCSG/SFOP Meeting, March 9 1996

15.     Capodano AM, Gaber J, Cannni H, Figarella D, Gentet JC, Bernard JL. Cytogenetic fluorescence in situ hybridation and molecular studies in a medulloblastoma with t(1;19). In: XXVIIIth SIOP Annual Meeting, Vienne, Octobre 1996

16.     Brunat-Mentigny M, Soler-Michel P, Demaille MC, Pacquement H, Abdelbost Z, Gentet JC, Krakowski Y. A pilot study of preoperative chemotherapy with 5 drugs in localised osteosarcoma f the extremities. In: XXVIIIth SIOP Annual Meeting, Vienne, 1996

17.     Bergeron C, Patte C, Leverger G, Gentet JC, Gandemer V, Perel Y, Lumley LD, Demeocq F, Dusol F, Baruchel A. Treatment of childhood lymphoblastic lymphomas. Results of the SFOP LMT 89 protocol. In: XXVIIIth Siop Annual Meeting, Vienne, Octobre 1996

18.     Beaugé F, Choquart D, Oliva L, Montet JC. Alleviation by ursodeoxycholate of liver plasma membrane disorders induced by alcohol intake in rats. In: Scientific Meeting of the Research Society on Alcoholism, Washington, Juin 1996

1995

1.       Pein F, Michon J, Valteau-Couanet D, Quintana E, Vannier JP, Frappaz D, Bergeron C, Barranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Zucker JM, Tournade MF. High-dose melphalan, etoposide and carboplatin with bone marrow transplantation as consolidation therapy in high-risk Wilms' tumors. 1995

2.       Namouni F, Doz F, Tanguy ML, Michon J, Pacquement H, Bouffet E, Gentet JC, Plantaz D, Lutz X, Vannier JP, Zucker JM. High dose chemotherapy with carboplatin, etoposide and cyclophosphamide with hematopoietic stem cell rescue in high risk retinoblastoma: a SFOP study. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

3.       Montet JC, Guitaoui M, Zamora AJ, Mesdjian E, Montet AM. L'acide ursodésoxycholique limite la stéatose alcoolique chez le rat. In,  1995

4.       Montet JC. Relations entre les propriétés physico-chimiques des sels biliaires et leurs effets biologiques. In: Symposium INSERM-Houdé, Paris, 1995

5.       Kalifa C, Raquin M, E.Bouffet, Gentet JC, Doz F, Chastagner P, Perel Y, Dowell MC. Chemotherapy without irradiation in medulloblastoma patient younger than three. A prospective study by the SFOP. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

6.       Kalifa C, Raquin M, Bouffet E, Gentet JC, Doz F, Chastagner P, Perel Y, Dowell H. Chemotherapy without irradiation in medulloblastoma patient younger than three. A prospective study by the SFOP. In: Proceedings of the American Society of Clinical Oncology, 1995

7.       Hartmann O, Valteau-Couanet D, Dupuis S, Doz F, Gentet JC, Mechinaud F, Bouffet E, Benhamou E, Kalifa C. High-dose chemotherapy followed by autologous bone marrow transplantation in place of cranio-spinal irradiation in young children treated for medulloblastoma? In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

8.       Gentet JC, Oberlin O, Voute T, Unnick AMJV, Terrier-Lacombe MJ, Morris-Jones PH, Tron P. Tumeurs rhabdoïdes extra-rénales. Série de la Société Internationale d' Oncologie Pédiatrique (SFOP) 1975-1993. In: XV° Forum de Cancérologie, Paris, Juin 1995

9.       Gentet JC, Brunat-Mentigny M, Kalifa C, Demaille MC, Pein F, Avet-Loiseau H, Freycon J, Lumley LD, Pacquement H, Schmitt C. Ifosfamide and etoposide in refractory or recurrent childhood osteosarcoma. A phase II study of the SFOP. 1995

10.     Figarella-Branger D, Gentet JC, Dubois C, Victor BD, Rougon G. Measurement of polysialylated isoforms of neural cell adhesion molecule (PSA-NCAM) in medulloblastoma. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

11.     Doz F, Gentet JC, Bouffet E, Demaille MC, Tron P, Roche H, Thyss A, Lejars O, Sariban E, Plantaz D, Freycon F, Brunat-Mentigny M, Bernard JL, Michon J, Carrie C, Alapetite C, Bours D, Zucker JM. Prolonged Sandwich Chemotherapy In Medulloblastoma: A Warning of the french M group. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

12.     Dalle JH, Patte C, Michon J, Gentet JC, Schmitt C, Mechinaud F, Lumley LD, Robert A, Thyss A. Curability without local treatment of testicular involvement in childhood B-cell lymphoma/leukemia. In: Proceedings of the American Society of Clinical Oncology, 1995

13.     Chastagner P, Kalifa C, Mechinaud-Lacroix F, Doz F, Bouffet E, Gentet JC, Babin A, Demaille MC, Otten J, Stephan JL, Lumley LD, Edan C, Couillault G, Thyss A, Plantaz D, Millot F, Tron P, Lemoine P. Phase II study of combined BCNU, cisplatin and VP 16 (BCV) for the treatment of high grade gliomas in children. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

14.     Chastagner P, Kalifa C, Doz F, Mechinaud-Lacroix F, Gentet JC, Babin A, Bouffet E, Demaille MC, Edan B, Otten J, Stephan JL, Lumley LD, Perilongo G, Thyss A, Lemoine P, Millot F, Tron P, Couillault G. Pilot study of combined BCNU, cisplatin and VP 16 (BCV) for the treatment of newly-diagnosed high grade gliomas in children. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995

15.     Berger C, Kalifa C, Balduck N, Faivre J, Bouffet E, Chazal J, Lumley LD, Demaille MC, Gentet JC, Wyss M, Freycon F, Stephan JL. Choroïd plexus carcinoma of childhood: report of the french experience. In: XXVIIth SIOP Annual Meeting, Montevideo, Octobre 1995